[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 194
1. Rodriguez AO, Truskinovsky AM, Kasrazadeh M, Leiserowitz GS: Case report: Malignant peripheral nerve sheath tumor of the uterine cervix treated with radical vaginal trachelectomy. Gynecol Oncol; 2006 Jan;100(1):201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Malignant peripheral nerve sheath tumor of the uterine cervix treated with radical vaginal trachelectomy.
  • BACKGROUND: Malignant peripheral nerve sheath tumors (MPNST) are rare tumors which occur primarily in major nerve trunks and most commonly in patients with neurofibromatosis.
  • CASE: We report a 22-year-old woman with MPNST of the uterine cervix which recurred after loop electrocautery excision and had positive margins on cone biopsy.
  • CONCLUSIONS: MPNST of the uterine cervix is a rare, but potentially aggressive neoplasm.
  • This is the first case of such a tumor treated successfully with preservation of the patients fertility.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Nerve Sheath Neoplasms / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Fertility. Gynecologic Surgical Procedures. Humans


2. Chamoun RB, Whitehead WE, Dauser RC, Luerssen TG, Okcu MF, Adesina AM, Jea A: Primary disseminated intradural malignant peripheral nerve sheath tumor of the spine in a child: case report and review of the literature. Pediatr Neurosurg; 2009;45(3):230-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary disseminated intradural malignant peripheral nerve sheath tumor of the spine in a child: case report and review of the literature.
  • The authors report a rare case of primary disseminated intradural malignant peripheral nerve sheath tumor (MPNST) of the spine in a 5-year-old child without neurofibromatosis type I (NF-I).
  • MRI revealed a large intradural extramedullary tumor at C4-5 with dissemination to the thoracic spine, cauda equina and leptomeninges.
  • Following a 2-level cervical laminectomy, the tumor was biopsied and debulked.
  • Based on pathological and immunohistological findings, the tumor was diagnosed as an MPNST.
  • The reported clinical outcomes for adult and pediatric patients with intradural MPNST are very poor.
  • We report the first pediatric case--without or with NF-I--of disseminated intradural MPNST primarily localized proximal to the conus medullaris.
  • [MeSH-major] Magnetic Resonance Imaging. Nerve Sheath Neoplasms / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19521138.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 38
  •  go-up   go-down


3. Zheng L, Zhang JG, Yu GY, Gao Y: [Malignant peripheral nerve sheath tumors in oral maxillofacial region: clinical analysis of 11 cases]. Beijing Da Xue Xue Bao; 2010 Apr 18;42(2):216-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peripheral nerve sheath tumors in oral maxillofacial region: clinical analysis of 11 cases].
  • OBJECTIVE: To investigate the clinicopathologic features, treatment and prognosis of the malignant peripheral nerve sheath tumors (MPNST) in oral and maxillofacial region.
  • CONCLUSION: MPNST is one of the most aggressive tumors with high risk of local recurrence and distant metastasis.
  • Complete removal of the tumor is the main modality of treatment and a most important prognostic factor of MPNST.
  • [MeSH-major] Mandibular Neoplasms / diagnosis. Maxillary Neoplasms / diagnosis. Mouth Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Child. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396368.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Gong YL, Li T, Guo H, Sun Y, Chi YK, Ling Y, Shen Q, Liu HJ, Hou L, Zhang B: [Expression of TEIF protein in soft tissue tumors and its significance]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):651-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of TEIF in 166 cases of sarcomas and 28 case benign tumors or tumor-like lesions of soft tissue arranged in tissue chip was analyzed by immunohistochemistry.
  • The immunohistochemical staining of TEIF showed that about 58% (97/166) of sarcomas were positive and significantly different from that of benign tumors or tumor-like lesions (11%, 3/28).
  • The positive staining was predominantly in synovial sarcoma 94% (16/17), primitive neuroectodermal tumor (PNET) 91% (21/23), both of which were significantly higher than 43% (6/14) of dermatofibrosarcoma protuberans, 38% (6/16) of myxofibrosarcoma, 36% (8/22) of malignant peripheral nerve sheath tumor, 32% (6/19) of liposarcoma, (P < 0.05, respectively), but not higher than 75% (15/20) of malignant fibrous histiocytoma, 70% (7/10) of rhabdomyosarcoma or 64% (9/14) of leiomyosarcoma.
  • Meanwhile, strong positive staining of TEIF (>or= 2+) was frequently observed in PNET (83%, 19/23) and synovial sarcoma (76%, 13/17).
  • With respect to FNCLCC grading, 19 cases of grade I sarcoma TEIF was 32% (6/19) and strong positive was 11% (2/19), 44 cases of grade II sarcoma was 48% (21/44) and 32% (14/44), and 70 of grade III was 84% (59/70) and 70% (49/70).
  • The rate of either positive or strong positive in grade III sarcoma was significantly different from that of either grade I or II (P < 0.05), but no difference between the latter two groups (P > 0.05).
  • [MeSH-major] Sarcoma / metabolism. Soft Tissue Neoplasms / metabolism. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Child. Child, Preschool. Female. HeLa Cells. Histiocytoma, Malignant Fibrous / metabolism. Histiocytoma, Malignant Fibrous / pathology. Humans. Immunohistochemistry. Infant. Leiomyoma / metabolism. Leiomyoma / pathology. Male. Middle Aged. Neuroectodermal Tumors, Primitive / metabolism. Neuroectodermal Tumors, Primitive / pathology. Rhabdomyosarcoma / metabolism. Rhabdomyosarcoma / pathology. Sarcoma, Synovial / metabolism. Sarcoma, Synovial / pathology. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374207.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Transcription Factors; EC 2.7.1.- / SCYL1 protein, human
  •  go-up   go-down


5. Jeong SY, Park SJ, Lee SJ, Park HJ, Kim HJ: Loss of Y chromosome in the malignant peripheral nerve sheet tumor of a patient with Neurofibromatosis type 1. J Korean Med Sci; 2010 May;25(5):804-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Y chromosome in the malignant peripheral nerve sheet tumor of a patient with Neurofibromatosis type 1.
  • In order to determine whether genomic alterations and/or chromosomal aberrations involved in the malignant progression of NF1 were present in a Korean patient with NF1, molecular and cytogenetic analyses were performed on the pathologically normal, benign, and malignant tissues and primary cells cultured from those tissues of the patient.
  • The comparative genomic hybridization (CGH) array revealed a Y chromosome loss in the malignant peripheral nerve sheet tumor (MPNST) tissue.
  • G-banding analysis of 50 metaphase cells showed normal chromosomal patterns in the histopathologically normal and benign cultured cells, but a mosaic Y chromosome loss in the malignant cells.
  • The final karyotype for the malignant cells from MPNST tissue was 45,X,-Y[28]/46,XY[22].
  • [MeSH-major] Chromosomes, Human, Y / genetics. Nerve Sheath Neoplasms / genetics. Neurofibromatosis 1 / genetics
  • [MeSH-minor] Humans. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • Genetic Alliance. consumer health - Peripheral type neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):11-6 [10564581.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):340-4 [11169957.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Pathol. 2002 May;197(1):98-107 [12081210.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):122-7 [15066319.001]
  • [Cites] Cancer Lett. 2004 May 10;208(1):95-101 [15105051.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):122-6 [8499945.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4778-81 [8840998.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Am J Med Genet. 1999 Jun 11;84(5):413-9 [10360395.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 1;166(1):56-64 [16616112.001]
  • [Cites] Clin Genet. 2007 Nov;72(5):411-9 [17916097.001]
  • [Cites] Cytogenet Genome Res. 2007;119(1-2):158-64 [18160797.001]
  • [Cites] Hum Mutat. 2008 Jan;29(1):74-82 [17960768.001]
  • [Cites] Semin Ophthalmol. 2008 Jan-Feb;23(1):45-51 [18214791.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1329-32 [18684036.001]
  • [Cites] Cancer Lett. 2000 Jul 31;155(2):181-90 [10822134.001]
  • (PMID = 20436723.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2858846
  • [Keywords] NOTNLM ; CGH Array / Chromosome Loss / G-banding / Nerve Sheath Neoplasms / Neurofibromatosis 1, Y chromosome
  •  go-up   go-down


6. Mantripragada KK, Díaz de Ståhl T, Patridge C, Menzel U, Andersson R, Chuzhanova N, Kluwe L, Guha A, Mautner V, Dumanski JP, Upadhyaya M: Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array. Genes Chromosomes Cancer; 2009 Oct;48(10):897-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array.
  • Neurofibromatosis Type I (NF1) is an autosomal dominant disorder characterized by the development of both benign and malignant tumors.
  • The lifetime risk for developing a malignant peripheral nerve sheath tumor (MPNST) in NF1 patients is approximately 10% with poor survival rates.
  • To date, the molecular basis of MPNST development remains unclear.
  • Here, we report the first genome-wide and high-resolution analysis of DNA copy number alterations in MPNST using the 32K bacterial artificial chromosome microarray on a series of 24 MPNSTs and three neurofibroma samples.
  • The profiles of malignant samples, however, revealed specific loss of chromosomal regions including 1p35-33, 1p21, 9p21.3, 10q25, 11q22-23, 17q11, and 20p12.2 as well as gain of 1q25, 3p26, 3q13, 5p12, 5q11.2-q14, 5q21-23, 5q31-33, 6p23-p21, 6p12, 6q15, 6q23-q24, 7p22, 7p14-p13, 7q21, 7q36, 8q22-q24, 14q22, and 17q21-q25.
  • Copy number gains were more frequent than deletions in the MPNST samples (62% vs. 38%).
  • [MeSH-major] Comparative Genomic Hybridization / methods. Genes, Neurofibromatosis 1. Nerve Sheath Neoplasms / genetics. Neurofibromatosis 1 / genetics. Oligonucleotide Array Sequence Analysis / methods. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Chromosome Aberrations. Chromosomes, Artificial, Bacterial. Female. Gene Dosage. Genome, Human. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19603524.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Widemann BC: Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep; 2009 Jul;11(4):322-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
  • Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas that rarely occur in the general population but have a lifetime incidence of 8% to 13% in those with neurofibromatosis type 1 (NF1).
  • The response rate of MPNSTs to standard chemotherapeutic agents used to treat pediatric and adult soft tissue sarcomas is unknown and is currently undergoing evaluation in a multi-institutional clinical trial.
  • This knowledge, coupled with the availability of preclinical MPNST models, likely will accelerate the development of effective treatments for this malignancy.
  • [MeSH-major] Nerve Sheath Neoplasms / genetics. Nerve Sheath Neoplasms / therapy. Neurofibromatosis 1 / complications
  • [MeSH-minor] Clinical Trials as Topic. DNA-Binding Proteins / genetics. Genetic Predisposition to Disease. Genome-Wide Association Study. Nuclear Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Protein p73. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics. Vascular Endothelial Growth Factor A / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):23-37 [14984765.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4507-13 [12154062.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8 [15937108.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1337-45 [14508395.001]
  • [Cites] J Pediatr. 1997 Nov;131(5):678-82 [9403645.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):791-6 [11821462.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1237-45 [18483311.001]
  • [Cites] J Neurosci Res. 2005 Nov 15;82(4):465-71 [16235251.001]
  • [Cites] Nature. 1992 Apr 23;356(6371):713-5 [1570015.001]
  • [Cites] Hum Mutat. 2008 Jan;29(1):74-82 [17960768.001]
  • [Cites] Histopathology. 2001 Aug;39(2):187-97 [11493336.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Curr Biol. 2008 Jan 8;18(1):56-62 [18164202.001]
  • [Cites] J Cell Physiol. 1998 Nov;177(2):334-42 [9766530.001]
  • [Cites] Cancer Treat Rep. 1985 May;69(5):499-504 [3924401.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):863-6 [2498525.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] Radiology. 2009 Mar;250(3):665-73 [19244040.001]
  • [Cites] Am J Med Genet. 1997 Dec 12;73(2):197-204 [9409873.001]
  • [Cites] Cancer. 1973 Aug;32(2):426-39 [4198700.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Neurology. 2005 Jul 26;65(2):205-11 [16043787.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Cancer. 1983 Mar 15;51(6):1028-33 [6821867.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Apr;12(2):355-68 [12916459.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):548-54; discussion 571-2, 646-51 [12403552.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):297-303 [15446585.001]
  • [Cites] Arch Surg. 1981 Jun;116(6):765-9 [7235973.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):390-4 [17932395.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):57-61 [11438454.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):593-8 [18559970.001]
  • [Cites] Neurosurg Clin N Am. 2008 Oct;19(4):533-43, v [19010279.001]
  • [Cites] Neuroradiology. 2003 Sep;45(9):618-25 [12898075.001]
  • [Cites] Exp Dermatol. 2003 Aug;12(4):412-7 [12930297.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] J Neurooncol. 2009 Sep;94(3):383-8 [19330289.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Mol Cancer. 2004 Jul 15;3:20 [15255999.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2543-9 [3922610.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Aug;113(1):65-9 [10459349.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] Am J Med Genet A. 2005 Jan 1;132A(1):49-53 [15523617.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8422-30 [16293873.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1520-8 [18316617.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):524-9 [8591083.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):69-73 [15346054.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1885-91 [10595919.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1253-65 [2119249.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4575-80 [7553632.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):31-7 [10469434.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):573-7; discussion 602-4, 646-51 [12403555.001]
  • [Cites] J Clin Invest. 2006 Apr;116(4):847-52 [16585951.001]
  • [Cites] Cell. 1992 Apr 17;69(2):265-73 [1568246.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Lancet Neurol. 2007 Apr;6(4):340-51 [17362838.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):1-5 [3791140.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2755-60 [15805275.001]
  • [Cites] Cancer Chemother Rep. 1970 Feb;54(1):65-8 [5527013.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):507-13 [8637706.001]
  • [Cites] Expert Rev Anticancer Ther. 2002 Apr;2(2):201-15 [12113242.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5536-41 [10554031.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):664-71 [16357008.001]
  • [Cites] Neurology. 2002 May 28;58(10):1461-70 [12041525.001]
  • [Cites] Acta Neuropathol. 2004 Feb;107(2):159-68 [14673600.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):65-75 [15652750.001]
  • [Cites] Neoplasia. 2007 Aug;9(8):671-7 [17786186.001]
  • (PMID = 19508838.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / TP53 protein, human; 0 / Tumor Protein p73; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 80
  •  go-up   go-down


8. Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Iwamoto Y, Tsuneyoshi M: Aberrant expression of CHFR in malignant peripheral nerve sheath tumors. Mod Pathol; 2006 Apr;19(4):524-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of CHFR in malignant peripheral nerve sheath tumors.
  • In MPNST, complex karyotypes showing numerical and structural aberrations have been described.
  • We examined the expression of CHFR in 96 cases of MPNST by immunohistochemical and molecular methods.
  • We found reduced (score, < or = 3) expression of CHFR in 63 out of 96 (66%) cases of MPNST, and such alteration was significantly correlated with a high mitotic count, a high Ki-67-labeling index, and a poor prognosis.
  • In addition, MPNST with normal karyotype showed a strong (score, =5) expression of CHFR.
  • Our results support the assertion that CHFR functions as an inhibitor of tumor proliferation.
  • [MeSH-major] Cell Cycle Proteins / genetics. Neoplasm Proteins / genetics. Nerve Sheath Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Infant. Ki-67 Antigen / analysis. Male. Middle Aged. Multivariate Analysis. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554732.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


9. Houreih MA, Eyden B, Deolekar M, Banerjee S: A case of fibroblastic low-grade malignant peripheral nerve sheath tumor--a true neurofibrosarcoma. Ultrastruct Pathol; 2007 Sep-Oct;31(5):347-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of fibroblastic low-grade malignant peripheral nerve sheath tumor--a true neurofibrosarcoma.
  • The authors report a case of low-grade retroperitoneal malignant peripheral nerve sheath tumor (MPNST) showing Schwannian and fibroblastic differentiation in individual tumor cells.
  • The tumor was detected in a 29-year-old male and posed diagnostic difficulty because of the unusual morphologic and immunophenotypic features.
  • Morphologic examination of the H&E sections revealed a rather circumscribed, highly vascular, moderately cellular spindle cell tumor.
  • There were satellite nodules outside the main tumor mass and low mitotic activity but no necrosis.
  • The tumor cells stained strongly and diffusely for both S-100 protein and CD34.
  • Although the capacity of MPNST to exhibit divergent differentiation is well known, fibroblastic differentiation is generally poorly and inconsistently documented.
  • The present case represents an unambiguous demonstration of the co-expression within individual tumor cells of Schwannian and fibroblastic differentiation in a low-grade MPNST.
  • [MeSH-major] Fibroblasts / pathology. Nerve Sheath Neoplasms / pathology. Neurofibrosarcoma / pathology
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Humans. Male. Microscopy, Electron, Transmission. S100 Proteins / analysis. Schwann Cells / ultrastructure

  • Genetic Alliance. consumer health - Neurofibrosarcoma.
  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963184.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


10. Mautner VF, Brenner W, Fünsterer C, Hagel C, Gawad K, Friedrich RE: Clinical relevance of positron emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibroma in NF1. Anticancer Res; 2007 Jul-Aug;27(4A):1819-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 1 (NF1) is a frequent and inherited disease with a predisposition for malignant peripheral nerve sheath tumor (MPNST) development.
  • MPNST are soft tissue sarcomas that arise from peripheral nerves, being one of the most aggressive malignancies in humans with extremely poor prognosis.
  • MPNST frequently arise from a previously undetected plexiform neurofibroma (PNF).
  • The malignant transformation of an internal PNF to an MPNST is difficult to assess and requires advanced imaging techniques like magnetic resonance imaging or positron emission tomography.
  • Despite the high quality of current diagnostics, the changing tumor biology inside a plexiform neurofibroma cannot currently be visualized accurately.
  • We report 4 cases of NF1 patients with PNF who showed imaging findings suspicious for malignant degeneration, but proved to have MPNST in only one case.
  • Three tumors might represent an intermediate type between PNF and MPNST.
  • Ablative surgery and complete histological work-up of specimens is the only way to clarify tumor status, thereby enabling provision of adequate local treatment.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Neurofibroma, Plexiform / diagnosis. Neurofibromatosis 1 / complications
  • [MeSH-minor] Adult. Child. Diagnosis, Differential. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Neurofibroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649778.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


11. Subhashraj K, Balanand S, Pajaniammalle S: Ancient schwannoma arising from mental nerve. A case report and review. Med Oral Patol Oral Cir Bucal; 2009 Jan;14(1):E12-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ancient schwannoma arising from mental nerve. A case report and review.
  • Schwannoma is an intraoral rare, benign neoplasm derived from the nerve sheath of peripheral nerves.
  • "Ancient schwannoma" shows histopathological features, such as degenerative changes and atypical nuclei, and may easily be confused with malignant neoplasms.
  • Ancient schwannoma of the head and neck region is relatively uncommon and very few cases had been reported in the oral cavity.
  • We present a case of ancient schwannoma arising from the mental nerve in a 19 year old male which was of eight months duration.
  • Ultrasonography showed that the tumor was closely associated with the mental nerve on the left side, suggestive of a peripheral neural sheath tumor.
  • Complete excision of the lesion was done under local anesthesia, preserving the mental nerve.
  • The histological picture was strongly suggestive of ancient schwannoma (Antoni A type).
  • [MeSH-major] Chin / innervation. Neurilemmoma / pathology. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Young Adult

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19114949.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 11
  •  go-up   go-down


12. Otsuka H, Graham MM, Kubo A, Nishitani H: FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case report. Ann Nucl Med; 2005 Feb;19(1):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • About 5% of patients with NF-1 develop sarcomatous transformation of a malignant peripheral nerve sheath tumor which arises from plexiform neurofibromas and is often associated with a poor prognosis.
  • Morphologic imaging techniques such as Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) are the standard methods to define the anatomic extent of the tumor, although tumor heterogeneity prevents reliable differentiation between benign and malignant lesions.
  • The degree of fluoro-deoxyglucose (FDG) uptake correlates with histologic grade in neurogenic tumors in NF-1 patients.
  • Our patient had a huge mass in the left gluteus area with a large nearly circular focus of increased FDG uptake in the tumor.
  • We surmised that the high FDG uptake indicated a high grade sarcoma, which was confirmed histologically.
  • FDG-PET/CT can identify sarcomatous change from benign neurogenic tumor with minimal misregistration, and can also detect metastatic disease.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Fluorodeoxyglucose F18. Neurofibromatoses / radiography. Neurofibromatoses / radionuclide imaging. Sarcoma / radiography. Sarcoma / radionuclide imaging. Subtraction Technique
  • [MeSH-minor] Adult. Humans. Male. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770975.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Santaella Y, Borrego I, López J, Ortiz MJ, Vázquez R: [18-FDG-PET in a case of recurrent malignant schwannoma]. Rev Esp Med Nucl; 2005 Mar-Apr;24(2):127-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18-FDG-PET in a case of recurrent malignant schwannoma].
  • [Transliterated title] Diagnóstico de recurrencia mediante FDG-PET en un caso clínico de schwannoma maligno.
  • The peripheral nerve sarcoma, also called malignant schwannoma, is originally a soft tissue sarcoma.
  • It is mainly located in the peripheral sheath nerve of the limbs and usually infiltrates the nerve fibres.
  • We present the case of a thirty year old woman with a malignant schwannoma in her left leg sciatic nerve who had been treated on several occasions.
  • PET can be a useful technique to detect recurrence for this kind of tumor, mainly in patients who have been previously radiated when the MRI is insufficient to perform a differential diagnosis between postirradiation fibrosis and tumoral recurrence, allowing for suitable therapeutic management of the patient.
  • [MeSH-major] Fluorodeoxyglucose F18. Neurilemmoma / radionuclide imaging. Peripheral Nervous System Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Sciatic Neuropathy / radionuclide imaging
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15745683.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Thomas C, Somani N, Owen LG, Malone JC, Billings SD: Cutaneous malignant peripheral nerve sheath tumors. J Cutan Pathol; 2009 Aug;36(8):896-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignant peripheral nerve sheath tumors.
  • Cutaneous malignant peripheral nerve sheath tumors (MPNSTs) are rare entities compared with their deep soft tissue counterparts.
  • The second case presented in an 88-year-old man with no stigmata of neurofibromatosis as a rapidly growing subcutaneous tumor of the right calf.
  • The diagnosis of MPNST was rendered in both cases.
  • [MeSH-minor] Adult. Aged, 80 and over. Female. Humans. Male. Mitosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586501.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


15. Keizman D, Issakov J, Meller I, Maimon N, Ish-Shalom M, Sher O, Merimsky O: Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol; 2009 Sep;94(3):383-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of EGFR in malignant peripheral nerve sheath tumor.
  • Malignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma.
  • The study was aimed at investigating the expression and prognostic influence of EGFR in MPNST.
  • Forty-three percentage of 46 patients with MPNST overexpressed EGFR in the primary tumor, and had a higher prevalence of advanced-stage tumors (>or=IIc, 46% vs. 80%, P = 0.011).
  • EGFR appeared to play a role in MPNST progression.
  • Clinical trials of targeting EGFR in MPNST are warranted.
  • [MeSH-major] Nerve Sheath Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2009 Sep;94(3):389. Meimon, Natalie [corrected to Maimon, Natalie]
  • [Cites] Oncologist. 2008 Apr;13(4):459-66 [18448562.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11 [12644979.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4507-13 [12154062.001]
  • [Cites] Cancer. 2005 May 1;103(9):1881-90 [15772959.001]
  • [Cites] Cell Signal. 2007 Oct;19(10):2013-23 [17681753.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):297-303 [15446585.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):585-90 [16461571.001]
  • [Cites] Sarcoma. 2008;2008:849156 [18769552.001]
  • [Cites] Am J Clin Pathol. 2006 Feb;125(2):229-33 [16393679.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] Neurosurg Focus. 2007 Jun 15;22(6):E12 [17613203.001]
  • [Cites] J Surg Oncol. 2007 Mar 1;95(3):183-4 [17323329.001]
  • [Cites] Eur J Surg Oncol. 2006 May;32(4):466-8 [16524687.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] Neuro Oncol. 2008 Dec;10 (6):946-57 [18650488.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1792-8 [9667648.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Surg Orthop Adv. 2005 Winter;14(4):168-74 [16442014.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] World J Surg Oncol. 2006 Aug 22;4:55 [16923196.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4057-65 [17827454.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1331-46 [11571750.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Breast Cancer. 2002;9(2):111-7 [12016390.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):65-75 [15652750.001]
  • (PMID = 19330289.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


16. Shimada S, Tsuzuki T, Kuroda M, Nagasaka T, Hara K, Takahashi E, Hayakawa S, Ono K, Maeda N, Mori N, Illei PB: Nestin expression as a new marker in malignant peripheral nerve sheath tumors. Pathol Int; 2007 Feb;57(2):60-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression as a new marker in malignant peripheral nerve sheath tumors.
  • Malignant peripheral nerve sheath tumor (MPNST) can be difficult to diagnose because it lacks specific immunohistochemical markers.
  • S-100, which is a useful marker of MPNST, has limited diagnostic utility.
  • The diagnostic utility of immunostains for nestin and three other neural markers (S-100, CD56 and protein gene product 9.5 (PGP 9.5)) were evaluated in 35 cases of MPNST and in other spindle cell tumors.
  • All MPNST cases were strongly positive for nestin and had cytoplasmic staining.
  • Nestin was negative in 10/10 leiomyomas, and weak nestin expression was seen in 10/10 schwannomas, 3/10 neurofibromas, 2/8 synovial sarcomas, 2/10 liposarcomas, 4/7 carcinosarcomas and 3/7 malignant fibrous histiocytomas.
  • Nestin is more sensitive for MPNST than other neural markers and immunostains for nestin in combination with other markers could be useful in the diagnosis of MPNST.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Intermediate Filament Proteins / metabolism. Nerve Sheath Neoplasms / metabolism. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cauda Equina / metabolism. Cauda Equina / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Child. Female. Gene Expression Regulation, Neoplastic. Humans. Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Male. Melanoma / metabolism. Melanoma / pathology. Middle Aged. Nestin. Neurilemmoma / metabolism. Neurilemmoma / pathology. Rhabdomyosarcoma / metabolism. Rhabdomyosarcoma / pathology. Sarcoma / metabolism. Sarcoma / pathology. Schwann Cells / metabolism. Schwann Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300669.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


17. Upadhyaya M, Kluwe L, Spurlock G, Monem B, Majounie E, Mantripragada K, Ruggieri M, Chuzhanova N, Evans DG, Ferner R, Thomas N, Guha A, Mautner V: Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat; 2008 Jan;29(1):74-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).
  • About 10% of neurofibromatosis type 1 (NF1) patients develop malignant peripheral nerve sheath tumors (MPNSTs) and represent considerable patient morbidity and mortality.
  • Elucidation of the genetic mechanisms by which inherited and acquired NF1 disease gene variants lead to MPNST development is important.
  • The NF1 germline mutation spectrum was similar to that previously identified in adult NF1 patients without MPNST.
  • Somatic NF1 mutations were identified in tumor DNA from 31 out of 34 MPNSTs, of which 28 were large genomic deletions.
  • The high prevalence (>90%) of such deletions in MPNST contrast with the =or<20% found in benign neurofibromas and is indicative of the involvement of different mutational mechanisms in these tumors.
  • [MeSH-major] Germ-Line Mutation. Mutation. Nerve Sheath Neoplasms / genetics. Neurofibromin 1 / genetics. Peripheral Nervous System Neoplasms / genetics
  • [MeSH-minor] Adult. DNA Mutational Analysis. DNA, Neoplasm / metabolism. Humans. Loss of Heterozygosity. Lymphocytes / metabolism. Sequence Deletion. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17960768.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neurofibromin 1; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


18. Levy AD, Patel N, Dow N, Abbott RM, Miettinen M, Sobin LH: From the archives of the AFIP: abdominal neoplasms in patients with neurofibromatosis type 1: radiologic-pathologic correlation. Radiographics; 2005 Mar-Apr;25(2):455-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations of the NF1 gene lead to abnormal tumor suppression.
  • Consequently, patients with NF1 have an increased prevalence of benign and malignant neoplasms throughout the body.
  • There are five categories of NF1 tumors that occur in the abdomen: neurogenic, neuroendocrine, nonneurogenic gastrointestinal mesenchymal, embryonal, and miscellaneous.
  • Malignant peripheral nerve sheath tumor is an aggressive malignancy that is the most common malignant tumor of the abdomen in patients with NF1.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nerve Sheath Neoplasms / diagnosis. Neuroendocrine Tumors / diagnosis. Neurofibroma / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798063.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 77
  •  go-up   go-down


19. Murovic JA, Gibbs IC, Chang SD, Mobley BC, Park J, Adler JR Jr: Foraminal nerve sheath tumors: intermediate follow-up after cyberknife radiosurgery. Neurosurgery; 2009 Feb;64(2 Suppl):A33-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Foraminal nerve sheath tumors: intermediate follow-up after cyberknife radiosurgery.
  • OBJECTIVE: To conduct a retrospective review of outcomes in 15 patients with 18 foraminal tumors, including 17 benign peripheral nerve sheath tumors and 1 malignant peripheral nerve sheath tumor, who underwent CyberKnife (Accuray, Inc., Sunnyvale, CA) radiosurgery at Stanford University Medical Center from 1999 to 2006.
  • METHODS: Symptoms and findings, neurofibromatosis (NF) association, previous radiation, imaging, dosimetry, tumor volume, central necrosis, and the relation of these factors to outcomes were evaluated.
  • Three patients had NF1-associated neurofibromas, 1 patient with NF2 had a schwannoma, and 1 patient had a schwannomatosis-related lesion.
  • Two likely radiation-induced lesions, a neurofibroma and a malignant peripheral nerve sheath tumor, were observed.
  • Prescribed doses ranging from 16 to 24 Gy, delivered in 1 to 3 fractions of 6 to 20 Gy, resulted in maximum tumor doses ranging from 20.9 to 30 Gy.
  • Tumor volumes decreased in 12 (67%) of 18 tumors and increased in 3 tumors.
  • Tumor volumes decreased in 8 of 10 schwannomas and 3 of 7 neurofibromas.
  • CONCLUSION: CyberKnife radiosurgery resulted in pain relief and functional preservation in selected foraminal peripheral nerve sheath tumors and a malignant peripheral nerve sheath tumor.
  • [MeSH-major] Nerve Sheath Neoplasms / surgery. Radiosurgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurofibromatoses / complications. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165072.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Yildirim G, Gillenwater AM, Ordonez NG, Garden AS, El-Naggar AK: Concurrent epithelioid malignant peripheral nerve sheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin's disease. Head Neck; 2008 May;30(5):675-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent epithelioid malignant peripheral nerve sheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin's disease.
  • A 1.5-cm papillary thyroid carcinoma was identified in thyroidectomy and an initial diagnosis of undifferentiated malignant neoplasm was rendered on the neck mass biopsy.
  • Subsequent surgical excision of the neck mass and immunohistochemical analysis revealed malignant peripheral nerve sheath tumor.
  • Rare malignancies including malignant peripheral nerve sheath tumor may be encountered along with the more common papillary thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / pathology. Neoplasms, Second Primary / pathology. Nerve Sheath Neoplasms / pathology. Peripheral Nervous System Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Epithelioid Cells / pathology. Female. Hodgkin Disease / radiotherapy. Humans. Neoplasms, Radiation-Induced / pathology. Neoplasms, Radiation-Induced / surgery. Thyroidectomy

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972308.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Hemalatha AL, Karthikeyan TM, Bharatnur SS, Kumar AS: Malignant peripheral nerve sheath tumor in oral cavity--a rare site. Indian J Pathol Microbiol; 2006 Jul;49(3):397-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor in oral cavity--a rare site.
  • MPNST occurring in oral cavity, which is a rare site for the tumour, in a 35 year old female patient with history of swelling underneath the tongue present since one year diagnosed clinically as ranula is presented here.
  • Histopathological examination of the excised mass showed features of spindle cell sarcoma following which a provisional diagnosis of MPNST was offered.
  • [MeSH-major] Mouth / pathology. Mouth Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001897.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


22. Brekke HR, Kolberg M, Skotheim RI, Hall KS, Bjerkehagen B, Risberg B, Domanski HA, Mandahl N, Liestøl K, Smeland S, Danielsen HE, Mertens F, Lothe RA: Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol; 2009 Oct;11(5):514-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors.
  • The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery.
  • We have used tissue microarrays (TMAs) to assess in situ expression of 14 cell-cycle-regulating proteins in 64 well-characterized MPNST patients: 36 sporadic and 28 with neurofibromatosis type 1 (NF1).
  • We developed a new software application for evaluation and logistics of the TMA images and performed a literature survey of cell cycle proteins in MPNST.
  • For the total series of MPNSTs, p53 was shown to be an independent predictor of survival, and patients without remission, with tumor size larger than 8 cm, and with positive p53 expression had a 60 times greater risk of dying within the first 5 years compared with the remaining patients (p = 0.000002).
  • This is the most comprehensive study of in situ protein expression in MPNST so far, and expressed p53 was found to be a strong surrogate marker for outcome.
  • Patients in complete remission with a primary p53-positive MPNST diagnosis may be considered in a high-risk subgroup and candidates for adjuvant treatment.
  • [MeSH-major] Biomarkers, Tumor / analysis. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Blotting, Western. Comparative Genomic Hybridization. Disease-Free Survival. Female. Gene Expression. Humans. Image Processing, Computer-Assisted / methods. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Software. Tissue Array Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Monogr Pathol. 1996;38:129-61 [8744276.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):13-25 [11145248.001]
  • [Cites] Lab Invest. 2001 Jun;81(6):833-44 [11406645.001]
  • [Cites] Arch Dermatol. 2001 Jul;137(7):908-13 [11453810.001]
  • [Cites] J Clin Pathol. 2001 Aug;54(8):631-6 [11477120.001]
  • [Cites] Histopathology. 2001 Aug;39(2):187-97 [11493336.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Virchows Arch. 2002 Jun;440(6):610-5 [12070601.001]
  • [Cites] J Pathol. 2002 May;197(1):98-107 [12081210.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 15;136(2):113-20 [12237234.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1337-45 [14508395.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4132-8 [14519636.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):69-73 [15346054.001]
  • [Cites] Anal Biochem. 1981 Apr;112(2):195-203 [6266278.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5435-9 [2142531.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1253-65 [2119249.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):122-6 [8499945.001]
  • [Cites] Cancer. 1994 May 15;73(10):2499-505 [8174045.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):282-8 [8816583.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4778-81 [8840998.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1443-9 [9414187.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):25-7 [9450543.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Mod Pathol. 1998 Jul;11(7):612-7 [9688181.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] Pediatr Dev Pathol. 1999 Jul-Aug;2(4):377-84 [10347283.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1841-7 [10362810.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Oct;26(2):151-60 [10469453.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jan;64(1):74-81 [15715087.001]
  • [Cites] Histopathology. 2006 Jan;48(1):42-50 [16359536.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):97-102 [16540739.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):524-32 [16554732.001]
  • [Cites] J Pathol. 2006 Aug;209(4):492-500 [16721726.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):187-92 [17111191.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):463-6 [17327286.001]
  • [Cites] Neoplasia. 2007 Aug;9(8):671-7 [17786186.001]
  • [Cites] Hum Mutat. 2008 Jan;29(1):74-82 [17960768.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1855-60 [10595915.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1879-84 [10595918.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1885-91 [10595919.001]
  • [Cites] J Pathol. 2000 Jan;190(1):31-8 [10640989.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):425-31 [10862051.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):250-5 [7522538.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):65-73 [7815081.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):793-8 [7790113.001]
  • [Cites] Virchows Arch. 1995;427(1):19-26 [7551341.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):202-6 [11135438.001]
  • (PMID = 19182148.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2765341
  •  go-up   go-down


23. Santarius T, Chia HL, Xuereb JH, Kirollos RW: Sporadic malignant nerve sheath tumour of the oculomotor nerve. Acta Neurochir (Wien); 2007 Jun;149(6):617-22; discussion 622
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic malignant nerve sheath tumour of the oculomotor nerve.
  • Malignant peripheral nerve sheath tumours (MPNST) are exceedingly rare in an intracranial location.
  • In this report clinical and pathological evidence for the diagnosis of a MPNST arising from of the oclumotor nerve is presented.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Nerve Sheath Neoplasms / surgery. Oculomotor Nerve Diseases / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Decompression, Surgical. Diagnosis, Differential. Diplopia / etiology. Female. Headache / etiology. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Microsurgery. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / diagnosis. Neoplasm, Residual / surgery. Ophthalmoplegia / etiology. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Radiosurgery. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17514351.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Shimada S, Ishizawa T, Ishizawa K, Matsumura T, Hasegawa T, Hirose T: The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers. Hum Pathol; 2006 Sep;37(9):1123-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) and dedifferentiated liposarcoma (DDL) are reported to have murine double-minute type 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) amplification as a characteristic genetic alteration.
  • To evaluate the diagnostic utility of this gene abnormality, we analyzed 19 liposarcomas, 21 malignant fibrous histiocytomas, 3 leiomyosarcomas, 5 malignant peripheral nerve sheath tumors, 23 lipomas, and 28 nonneoplastic fat tissues using real-time polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH).
  • In FISH, all ALT/WDLs and DDLs had both MDM2 and CDK4 amplifications, and all of the myxoid/round cell liposarcomas, leiomyosarcomas, malignant peripheral nerve sheath tumors, and all but one of the malignant fibrous histiocytomas did not have the amplifications.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cyclin-Dependent Kinase 4 / genetics. Liposarcoma / diagnosis. Liposarcoma / genetics. Proto-Oncogene Proteins c-mdm2 / genetics
  • [MeSH-minor] Adipose Tissue / pathology. Adipose Tissue / physiology. Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Amplification. Histiocytoma, Malignant Fibrous / diagnosis. Histiocytoma, Malignant Fibrous / genetics. Humans. In Situ Hybridization, Fluorescence. Infant. Leiomyosarcoma / diagnosis. Leiomyosarcoma / genetics. Lipoma / diagnosis. Lipoma / genetics. Male. Middle Aged. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938516.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


25. Okoshi A, Shiga K, Sasaki K, Asada Y, Nishikawa H, Kobayashi T, Watanabe M: [Two cases of radiation-induced sarcoma after radiation therapy in nasopharyngeal carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):533-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of radiation-induced sarcoma after radiation therapy in nasopharyngeal carcinoma].
  • We report two cases of radiation-induced sarcoma after chemoradiation therapy in nasopharyngeal carcinoma.
  • Case 1: A 40-year-old man developed a malignant peripheral nerve sheath tumor (MPNST) in the posterior floor of the nasal cavity 10 years after treatment for nasopharyngeal cancer.
  • Case 2: A 64 year-old man developed a malignant fibrous histiocytoma (MFH) of the lower gum 10 years after treatment of nasopharyngeal cancer.
  • Despite radical surgery, the man with MPNST had a recurrent tumor and died of the disease.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / etiology. Nasopharyngeal Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Nerve Sheath Neoplasms / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697477.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


26. Luna-Ortiz K, Navarrete-Alemán JE, Granados-García M, Herrera-Gómez A: Primary parapharyngeal space tumors in a Mexican cancer center. Otolaryngol Head Neck Surg; 2005 Apr;132(4):587-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixteen (76%) patients had benign lesions and 5 (24%) had malignant tumors.
  • Neurogenic tumors represented 57% of all tumors.
  • Mean tumor size was of 6.7 cm (range, 3 to 11 cm).
  • Complications occurred in 6 (29%) patients, 4 (19%) of which were nervous injuries associated with peripheral nerve sheath tumors.
  • Conversion to mandibular swing approach when the cervical approach is not offering proper exposure for tumor resection is indicated.
  • Nevertheless, CT scan should always be performed in order to exclude paragangliomas, distinguish prestyloid from poststyloid lesions, and to assess the extension of the tumor as well as its relationship with adjacent structures.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Neurilemmoma / diagnosis. Pharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / mortality. Adenoma, Pleomorphic / pathology. Adenoma, Pleomorphic / radiotherapy. Adenoma, Pleomorphic / surgery. Adult. Aged. Biopsy, Fine-Needle. Cancer Care Facilities. Cervical Vertebrae / surgery. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Mexico. Middle Aged. Parotid Gland / pathology. Parotid Gland / surgery. Pharyngectomy / methods. Pharynx / pathology. Postoperative Complications / etiology. Postoperative Complications / mortality. Radiotherapy, Adjuvant. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806051.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Wasa J, Nishida Y, Tsukushi S, Shido Y, Sugiura H, Nakashima H, Ishiguro N: MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR Am J Roentgenol; 2010 Jun;194(6):1568-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas.
  • OBJECTIVE: The objective of this study was to identify the MRI criteria that best differentiate malignant peripheral nerve sheath tumors from benign neurofibromas.
  • MATERIALS AND METHODS: We retrospectively analyzed MR images obtained for 41 histologically diagnosed cases of malignant peripheral nerve sheath tumor and 20 cases of neurofibroma that had been treated at four tertiary institutions.
  • Twenty of the patients with malignant peripheral nerve sheath tumors and 14 patients with neurofibromas developed the disease in association with neurofibromatosis 1.
  • The MR images were evaluated with regard to tumor size, signal intensity, heterogeneity of T1- and T2-weighted MR images, enhancement pattern, definition of margins, presence of perilesional edemalike zone, and presence of intratumoral cystic lesions.
  • RESULTS: Significant differences between malignant peripheral nerve sheath tumors and neurofibromas were noted for the largest dimension of the mass, peripheral enhancement pattern, perilesional edemalike zone, and intratumoral cystic lesion.
  • In cases associated with neurofibromatosis 1, heterogenicity on T1-weighted images was also significant in differentiating neurofibroma from malignant peripheral nerve sheath tumor.
  • The presence of two or more of the four features suggestive of malignancy indicated malignant peripheral nerve sheath tumor with a sensitivity of 61% and a specificity of 90%.
  • CONCLUSION: The MR features described in this study are useful for distinguishing malignant peripheral nerve sheath tumors from neurofibromas.
  • If a tumor has two or more of the four statistically significant features, it can be considered to be highly suspicious of malignancy and should be subjected to a biopsy for early diagnosis.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Nerve Sheath Neoplasms / diagnosis. Neurofibromatosis 1 / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Contrast Media. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neurofibroma / diagnosis. Neurofibroma / pathology. Retrospective Studies. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489098.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


28. Kresse SH, Skårn M, Ohnstad HO, Namløs HM, Bjerkehagen B, Myklebost O, Meza-Zepeda LA: DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. Mol Cancer; 2008;7:48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.
  • BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are rare and highly aggressive soft tissue tumors showing complex chromosomal aberrations.
  • In order to identify recurrent chromosomal regions of gain and loss, and thereby novel gene targets of potential importance for MPNST development and/or progression, we have analyzed DNA copy number changes in seven high-grade MPNSTs using microarray-based comparative genomic hybridization (array CGH).
  • CONCLUSION: Our study shows the potential of using DNA copy number changes obtained by array CGH to predict the prognosis of MPNST patients.
  • [MeSH-major] DNA, Neoplasm / analysis. Gene Dosage. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Nerve Sheath Neoplasms / genetics. Oligonucleotide Array Sequence Analysis. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adenovirus E1A Proteins / genetics. Adult. Aged. Amino Acid Oxidoreductases / genetics. Antigens, Neoplasm / genetics. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 8. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Female. Gene Expression Regulation, Enzymologic. Humans. Inhibitor of Apoptosis Proteins. Male. Microtubule-Associated Proteins / genetics. Middle Aged. Neoplasm Proteins / genetics. Prognosis. Proto-Oncogene Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer. 2004 Jul 15;3:20 [15255999.001]
  • [Cites] BMC Bioinformatics. 2004 Jun 9;5:74 [15189572.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1172-8 [15509679.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):793-8 [7790113.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Sep;14(1):8-14 [8527390.001]
  • [Cites] Monogr Pathol. 1996;38:129-61 [8744276.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4778-81 [8840998.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jul;25(3):205-11 [10379866.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):323-31 [10398425.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):362-9 [10398430.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):1-6 [10469430.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Oct;26(2):151-60 [10469453.001]
  • [Cites] Bioinformatics. 2005 Mar15;21(6):821-2 [15531610.001]
  • [Cites] Mutat Res. 2005 Aug 25;576(1-2):22-38 [15878778.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):297-303 [16391845.001]
  • [Cites] J Clin Pathol. 2006 Feb;59(2):160-5 [16443732.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1087-98 [16731740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 [16754881.001]
  • [Cites] J Pathol. 2006 Aug;209(4):492-500 [16721726.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8984-93 [16982739.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6202-10 [17028600.001]
  • [Cites] Trends Mol Med. 2006 Dec;12(12):580-7 [17071139.001]
  • [Cites] J Orthop Res. 2007 Jan;25(1):116-21 [17034065.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):187-92 [17111191.001]
  • [Cites] BMC Genomics. 2007;8:73 [17359542.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jul;46(7):644-55 [17394133.001]
  • [Cites] J Pathol. 2000 Jan;190(1):31-8 [10640989.001]
  • [Cites] Cancer Lett. 2000 Jul 31;155(2):181-90 [10822134.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Pathol. 2002 May;197(1):98-107 [12081210.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1657-66 [12670920.001]
  • [Cites] J Pathol. 2003 Aug;200(5):568-76 [12898592.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4132-8 [14519636.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Carcinogenesis. 2004 Mar;25(3):325-32 [14604892.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):69-73 [15346054.001]
  • (PMID = 18522746.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / ETV4 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; EC 1.4.- / Amino Acid Oxidoreductases; EC 1.4.3.- / LOXL2 protein, human; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2442610
  •  go-up   go-down


29. Huang W, Zhang X, Li D, Chen J, Meng K, Wang Y, Lu Z, Zhou X: Osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcoma of soft parts. Virchows Arch; 2006 Feb;448(2):200-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcoma of soft parts.
  • Clear cell sarcoma is a high-grade sarcoma with morphological features resembling those of malignant melanoma.
  • An osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts is very rare.
  • Herein, we report an unusual stomach tumor with microscopic and immunohistochemical characteristics of an osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts.
  • The tumor cells were predominantly oval, admixed with some round and spindle elements arranged in nests and fascicles, and admixed with scattered osteoclast-like multinucleated giant cells.
  • The unusual morphology of the tumor caused significant diagnostic difficulties.
  • The differential diagnosis included gastrointestinal stromal tumor, primary or metastatic melanoma, and epithelioid malignant peripheral nerve sheath tumor.
  • To the best of our knowledge, this is possibly the second description of an osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Osteoclasts / pathology. Sarcoma, Clear Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Diagnosis, Differential. Giant Cells / chemistry. Giant Cells / pathology. Humans. Immunohistochemistry. Male. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1042-4 [10570398.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):438-40 [10705403.001]
  • [Cites] Adv Anat Pathol. 1999 Jan;6(1):19-40 [10197236.001]
  • [Cites] Arch Pathol Lab Med. 2002 Aug;126(8):972-4 [12171499.001]
  • [Cites] Pathologica. 1998 Aug;90(4):388-90 [9793400.001]
  • [Cites] Int J Surg Pathol. 2003 Apr;11(2):75-81 [12754623.001]
  • [Cites] Ann Thorac Surg. 1985 May;39(5):472-75 [3994450.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4424-7 [9751528.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):969-75 [10491522.001]
  • [Cites] Histopathology. 1993 Mar;22(3):255-9 [7684355.001]
  • [Cites] J Clin Pathol. 2001 Feb;54(2):96-102 [11215292.001]
  • [Cites] Indian J Gastroenterol. 1999 Oct-Nov;18(4):176 [10531723.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):121-4 [9422325.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):440-3 [15043462.001]
  • [Cites] Gen Diagn Pathol. 1996 Jun;142(1):63-7 [8793489.001]
  • [Cites] Am Surg. 1992 Jul;58(7):418-22 [1616187.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Gut. 1991 Jul;32(7):828-30 [1855693.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Histopathology. 2002 Dec;41(6):526-30 [12460205.001]
  • [Cites] J Cell Biochem. 1998 Jul 1;70(1):121-9 [9632113.001]
  • (PMID = 16220298.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / S100 Proteins
  •  go-up   go-down


30. Allison KH, Patel RM, Goldblum JR, Rubin BP: Superficial malignant peripheral nerve sheath tumor: a rare and challenging diagnosis. Am J Clin Pathol; 2005 Nov;124(5):685-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial malignant peripheral nerve sheath tumor: a rare and challenging diagnosis.
  • We reviewed the clinicopathologic features of 5 cases of malignant peripheral nerve sheath tumor (MPNST) manifesting in superficial locations associated with cutaneous neurofibromas (4 cases) or superficial peripheral nerve (1 case).
  • However, identification of a benign precursor or origin from a nerve may be the most definitive way to properly classify these rare lesions.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203275.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins
  •  go-up   go-down


31. Kang GH, Kim KM, Noh JH, Sohn TS, Kim S, Park CK, Lee CS, Kang DY: WT-1 expression in gastrointestinal stromal tumours. Pathology; 2010 Jan;42(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leiomyosarcomas, schwannomas, malignant peripheral nerve sheath tumours (MPNSTs) and melanomas showed cytoplasmic staining, whereas leiomyomas and mesenteric fibromatoses were totally negative for WT-1.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gastrointestinal Stromal Tumors / metabolism. Soft Tissue Neoplasms / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytoplasm / metabolism. Cytoplasm / pathology. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Receptor, Platelet-Derived Growth Factor alpha / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025481.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / WT1 Proteins; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


32. Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A: Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery; 2009 Oct;65(4 Suppl):A160-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
  • OBJECTIVE: Benign plexiform neurofibromas (PNfib), especially those occurring in patients with neurofibromatosis type 1, are at a significant risk of progressing to a malignant peripheral nerve sheath tumor (MPNST).
  • Early diagnosis, followed by radical surgery and adjuvant radiation to maintain local tumor control, is of critical importance to prevent metastasis and subsequent mortality from MPNSTs.
  • However, early diagnosis is hampered by the sensitivity of current imaging modalities such as computed tomography (CT) or magnetic resonance imaging to reliably detect this malignant transformation, which can occur heterogeneously in a PNfib to a MPNST.
  • METHODS: In this prospective study, 9 neurofibromatosis type 1-associated PNfibs suspected to have undergone transformation to an MPNST were preoperatively evaluated by 18FDG-PET/CT and magnetic resonance imaging.
  • A detailed histological evaluation correlated the average and regional standard uptake value (SUV) from the 18FDG-PET/CT to grade of malignancy of the suspected MPNST.
  • Stratification of the maximal SUV to low (<4.0), intermediate (4.0-7.0), or high (>7.0) correlated to the proliferative index (Ki-67) and grade of MPNST.
  • A maximal SUV of more than 7.0 was closely correlated to a focus of malignant transformation.
  • [MeSH-major] Nerve Sheath Neoplasms / radionuclide imaging. Neurofibroma / radionuclide imaging. Neurofibromatosis 1 / radionuclide imaging. Peripheral Nerves / radionuclide imaging. Peripheral Nervous System Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Tomography, X-Ray Computed. Young Adult


33. Matsumine A, Shintani K, Kusuzaki K, Matsubara T, Satonaka H, Wakabayashi T, Iino T, Uchida A: Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol; 2007 Oct 1;96(5):411-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Lower levels of decorin were expressed in liposarcoma and malignant peripheral nerve sheath tumor than in lipoma (<0.01) and neurofibroma (P < 0.05), respectively.
  • An immunohistochemical analysis for spindle-cell sarcomas demonstrated decorin protein to be produced by myofibroblastic cells in the peripheral stromal extracellular spaces.
  • CONCLUSIONS: A reduced decorin expression was found to be a useful biomarker of aggressiveness in soft tissue tumor.
  • [MeSH-major] Extracellular Matrix Proteins / metabolism. Neoplasms, Connective and Soft Tissue / metabolism. Nerve Sheath Neoplasms / metabolism. Proteoglycans / metabolism. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Child. Child, Preschool. DNA, Neoplasm / metabolism. Decorin. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Proportional Hazards Models. RNA, Neoplasm / metabolism. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17579351.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DCN protein, human; 0 / DNA, Neoplasm; 0 / Decorin; 0 / Extracellular Matrix Proteins; 0 / Proteoglycans; 0 / RNA, Neoplasm
  •  go-up   go-down


34. Melliou A, Karamouzis J, Helis L, Mouzakiti A, Theocharidis G, Karkavelas G, Kouroussis C: Malignant peripheral nerve-sheath tumor of the left cerebello-pontine angle: case report. J BUON; 2006 Jul-Sep;11(3):367-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve-sheath tumor of the left cerebello-pontine angle: case report.
  • [MeSH-major] Cerebellar Neoplasms. Cerebellopontine Angle. Nerve Sheath Neoplasms
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309166.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


35. Park SK, Yi HJ, Paik SS, Kim YJ, Ko Y, Oh SJ: Metastasizing malignant peripheral nerve sheath tumor initially presenting as intracerebral hemorrhage. Case report and review of the literature. Surg Neurol; 2007 Jul;68(1):79-84; discussion 84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing malignant peripheral nerve sheath tumor initially presenting as intracerebral hemorrhage. Case report and review of the literature.
  • BACKGROUND: Malignant peripheral nerve sheath tumors, infrequent sarcomas arising within a peripheral nerve, mostly metastasize to the lung at terminal stage of disease.
  • Surgical removal and adjuvant therapy was performed for pathologically proven MPNST.
  • Concurrent painful chest masses were also confirmed as MPNST through surgical resection.
  • The MPNST actually can exhibit an apoplectic manifestation even without pulmonary involvement in a young adult, albeit this is quite rare.
  • Thus, high index of suspicion should be paid to minute complaints regarding MPNST in peripheral locations so as not to overlook an advanced or metastasized disease.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Cerebral Hemorrhage / etiology. Nerve Sheath Neoplasms / complications. Nerve Sheath Neoplasms / secondary. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adult. Craniotomy. Fatal Outcome. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586234.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


36. Shah H, Pervez S: Immunophenotypic characterization of high grade pleomorphic sarcomas: a demographic and immunohistochemical study in a major referral center of Pakistan. J Pak Med Assoc; 2005 Mar;55(3):101-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 134 cases which were characterized, 38.1% were pleomorphic leiomyosarcoma, followed by pleomorphic rhabdomyosarcoma 14.9%, Malignant Peripheral Nerve Sheath Tumour 9%, pleomorphic liposarcoma 3.7% and pleomorphic storiform Malignant Fibrous Histiocytoma 0.7%.
  • Mean/ median age for Leiomyosarcoma was 50/50, for Rhabdomyosarcomas 33/22, for MPNST 42/41, for Liposarcoma 52/50 and for Malignant Fibrous Histiocytoma 46/46 respectively.
  • CONCLUSION: It was concluded that the most common pleomorphic sarcoma occurring in our adult population was Leiomyosarcoma, and that immunohistochemical stains are essential in most cases for further characterization of pleomorphic high grade sarcoma.
  • [MeSH-major] Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Antigens, Neoplasm / immunology. Biomarkers, Tumor / analysis. Cross-Sectional Studies. Humans. Immunoenzyme Techniques. Immunohistochemistry. Leiomyosarcoma / pathology. Liposarcoma / genetics. Liposarcoma / pathology. Middle Aged. Nerve Sheath Neoplasms / genetics. Nerve Sheath Neoplasms / pathology. Pakistan. Phenotype. Rhabdomyosarcoma / genetics. Rhabdomyosarcoma / pathology. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852744.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Spurlock G, Griffiths S, Uff J, Upadhyaya M: Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types. Fam Cancer; 2007;6(4):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types.
  • We have carried out NF1 gene mutation analysis on DNA isolated from 25 tumours (dermal and plexiform neurofibromas, malignant peripheral nerve sheath tumour, MPNST), obtained at post-mortem from an NF1 patient.
  • [MeSH-minor] Adolescent. Adult. Alleles. Base Sequence. Child, Preschool. Chromatography, High Pressure Liquid. Exons / genetics. Gene Deletion. Humans. Microsatellite Instability. Molecular Sequence Data. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 1988 Dec;111 ( Pt 6):1355-81 [3145091.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Oct;45(10):893-904 [16830335.001]
  • [Cites] Hum Genet. 2003 Feb;112(2):117-23 [12522551.001]
  • [Cites] Hum Mutat. 2003 Dec;22(6):423-7 [14635100.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):237-47 [10607834.001]
  • [Cites] Am J Hum Genet. 2000 Feb;66(2):393-401 [10677298.001]
  • [Cites] Hum Genet. 2001 May;108(5):416-29 [11409870.001]
  • [Cites] Am J Med Genet. 1997 May 16;70(2):138-43 [9128932.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):111-6 [14722914.001]
  • [Cites] Acta Derm Venereol. 1995 Mar;75(2):136-40 [7604643.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):134-46 [14722917.001]
  • [Cites] Hum Mutat. 2006 Oct;27(10 ):1030-40 [16941471.001]
  • [Cites] Hum Mutat. 1997;9(5):458-64 [9143927.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6977 [1762941.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12 ):e57 [12060695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 19;234(2):346-50 [9177273.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):290-3 [9927033.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):359-62 [11809679.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):425-31 [10862051.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):122-6 [8499945.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 [16283621.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Aug;113(1):65-9 [10459349.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):294-7 [9927034.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] J Med Genet. 2000 Jan;37(1):44-9 [10633134.001]
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):790-818 [10712197.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Am J Hum Genet. 1994 Mar;54(3):424-36 [8116612.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):110-2 [8782831.001]
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1387-92 [11440991.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):90-2 [7550323.001]
  • (PMID = 17551851.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


38. Stark AM, Mehdorn HM: Multiple intracranial metastases from a malignant peripheral nerve sheath tumor of the extremities. J Neurooncol; 2006 Jun;78(2):209-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple intracranial metastases from a malignant peripheral nerve sheath tumor of the extremities.
  • [MeSH-major] Brain Neoplasms / secondary. Lung Neoplasms / secondary. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Growth Hormone / metabolism. Humans. Male. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / pathology. Thigh. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 2001;143(4):357-63; discussion 363-4 [11437289.001]
  • [Cites] Neurology. 2003 Sep 9;61(5):696-8 [12963767.001]
  • [Cites] Folia Neuropathol. 2004;42(1):43-8 [15119745.001]
  • [Cites] Gen Diagn Pathol. 1997 Jun;142(5-6):357-60 [9228261.001]
  • (PMID = 16598432.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


39. Kushida Y, Haba R, Kobayashi S, Ishikawa M, Doi T, Kadota K: Ectopic hamartomatous thymoma: a case report with immunohistochemical study and review of the literature. J Cutan Pathol; 2006 May;33(5):369-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ectopic hamartomatous thymoma (EHT) is a rare benign tumor.
  • The tumor consisted of spindle cells, epithelial cells, adipose cells, and a small amount of lymphocytes, as described previously.
  • Recognition of EHT is important and needs to be differentiated from high-grade sarcomas such as synovial sarcoma or glandular malignant peripheral nerve sheath tumor.
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, CD1 / metabolism. Antigens, CD20 / metabolism. Antigens, CD34 / metabolism. Antigens, CD45 / metabolism. Cell Adhesion Molecules / metabolism. Diagnosis, Differential. Humans. Keratins / metabolism. Male. Nerve Sheath Neoplasms / pathology. Sarcoma, Synovial / metabolism. Sarcoma, Synovial / pathology. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640545.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD1; 0 / Antigens, CD20; 0 / Antigens, CD34; 0 / CD1a antigen; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Vimentin; 68238-35-7 / Keratins; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


40. Landy H, Feun L, Markoe A, Patchen S, Bruce J, Marcus J, Levi A: Extended remission of a recurrent median nerve malignant peripheral nerve sheath tumor after multimodal treatment. Case report. J Neurosurg; 2005 Oct;103(4):760-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended remission of a recurrent median nerve malignant peripheral nerve sheath tumor after multimodal treatment. Case report.
  • Malignant peripheral nerve sheath tumors (MPNSTs) are difficult to control despite aggressive treatment.
  • In this report the authors describe the treatment and follow-up review of a patient with neurofibromatosis Type I who harbored a recurrent median nerve MPNST.
  • Two courses of preoperative intraarterial cisplatin and intravenous Adriamycin produced significant tumor shrinkage.
  • Gross-total removal of the remaining tumor without amputation of the arm was followed by fractionated radiotherapy (total minimum tumor dose 6485 cGy, maximal dose 6575 cGy).
  • The patient is alive 9.5 years after treatment without evidence of tumor recurrence and with only focal median nerve functional deficits.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Nerve Sheath Neoplasms / surgery. Neurofibromatosis 1 / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Male. Treatment Outcome


41. Ziadi A, Saliba I: Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review. Auris Nasus Larynx; 2010 Oct;37(5):539-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review.
  • OBJECTIVES: The incidence of malignant peripheral nerve sheath tumor (MPNST) is approximately 0.001%.
  • (1) to review all cases of intracranial MPNST described in the literature, (2) to highlight the suspicion of intracranial MPNST, (3) to identify the gross pathology, the histopathology, the immunohistochemistry, (4) to discuss the differential diagnosis, the treatment, the recurrence rate, the follow-up, the incidence of metastasis and the prognosis.
  • We used the following Keywords: "malignant peripheral nerve sheath tumor", "cranial nerve", "neurosarcoma", "malignant schwannoma", "neurofibroma", "malignant neurofibroma" and "nerve tumor".
  • We considered cases where MPNST involved an intracranial cranial nerve.
  • RESULTS: We identified 32 cases of cranial MPNST including our case.
  • Most cases are developed sporadically (50%), 31% arise from a malignant transformation of schwannoma and 19% from a neurofibroma.
  • The cranial nerve VIII is the most involved (15/32), followed by the Vth (10/32) and the VIIth (5/32).
  • MPNST will strongly express protein S-100 and collagen IV-laminin.
  • 13 cases were treated with radiotherapy for tumor recurrence and metastasis.
  • CONCLUSION: MPNST of cranial nerves are very rare.
  • In neurofibroma, even though MPNST is mainly associated to type 1, we should keep in mind its association to NF2.
  • Inaccessibility of cranial MPNST may explain the subtotal resection and thus the poor prognosis.
  • [MeSH-major] Cranial Nerve Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic / pathology. Child. Child, Preschool. Diagnosis, Differential. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neurilemmoma / diagnosis. Neurilemmoma / pathology. Neurilemmoma / radiotherapy. Neurilemmoma / surgery. Neurofibroma / diagnosis. Neurofibroma / pathology. Neurofibroma / radiotherapy. Neurofibroma / surgery. Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / pathology. Neurofibromatosis 1 / radiotherapy. Neurofibromatosis 1 / surgery. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / pathology. Neurofibromatosis 2 / radiotherapy. Neurofibromatosis 2 / surgery. Radiotherapy, Adjuvant. Spinal Neoplasms / mortality. Spinal Neoplasms / pathology. Spinal Neoplasms / secondary. Young Adult

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20399579.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 35
  •  go-up   go-down


42. Guo H, Xiong Y, Nong L, Zhang S, Li T: [Reassessment of the pathological diagnosis in 33 cases of malignant fibrous histiocytoma]. Beijing Da Xue Xue Bao; 2008 Aug 18;40(4):374-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reassessment of the pathological diagnosis in 33 cases of malignant fibrous histiocytoma].
  • OBJECTIVE: Since malignant fibrous histiocytoma (MFH) may be taken as an undifferentiated pleomorphic sarcoma (UPS), this study was conducted to reassess 33 previously diagnosed MFH cases in the past 10 years based on the latest WHO concept.
  • METHODS: Thirty-three cases in tissue microarray were studied by immunohistochemistry with panels of neurogenic, myogenic, and lipogenic antibodies.
  • RESULTS: Among the 33 cases, 17 cases (51.5%) of MFH had their diagnoses changed, including 5 leiomyosarcomas, 3 malignant peripheral nerve sheath tumors, 1 fibrosarcoma, 1 inflammatory myofibrosarcoma, 1 giant cell tumor and 1 angiomatoid fibrous histiocytoma.
  • The median tumor size was 6.0 cm (range: 3.0 to 14.0 cm), 8 cases (50%) located in lower limb and 5 cases (31.3%) located in thigh.
  • Eleven cases (68.8%) variously expressed CD68 (KP1) and 7 cases (43.8%) expressed CD68 (PG-M1), which were much higher than leiomyosarcoma, malignant peripheral nerve sheath tumor and liposarcoma with significant difference.
  • CONCLUSION: MFH/UPS often show marked histological pleomorphism, and the diagnosis must be made by exclusion of other definitive sarcomas, especially myogenic and neurogenic sarcoma.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677383.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


43. Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, Upadhyaya M: Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol; 2010 Dec;136(12):1869-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
  • OBJECTIVE: Neurofibromatosis type 1 (NF1) patients have a 13% risk of developing a malignant peripheral nerve sheath tumor (MPNST).
  • Many MPNSTs are histopathologically complex, with regions exhibiting features of the original benign plexiform neurofibroma (PNF), of an atypical PNF, or of MPNST showing varying degrees of de-differentiation.
  • This study analyzed the genetic alterations associated with this pathological heterogeneity in order to identify the genetic processes involved in transformation from a benign to an aggressive malignant tumor.
  • METHODS: A histological and molecular analysis of a single MPNST tumor that was subdivided into three histopathologically distinct regions, a benign PNF (region 1), an atypical PNF (region 2), and a high-grade MPNST (region 3), was carried out.
  • Tumor DNA from each region was analyzed in conjunction with the patient's lymphocyte DNA.
  • The NF1-associated LOH analysis found that LOH increased in the three tumor areas, with 9, 42, and 97% LOH evident in regions 1, 2, and 3, respectively.
  • Additional genetic changes, including losses of TP53, RB1, CDKN2A, and of several oncogenes and cell-cycle genes, were found only in the malignant MPNST (region 3).
  • DISCUSSION: This is the first study that correlates the histological and molecular changes associated with MPNST development, confirming the significant cellular and genetic heterogeneity that poses both diagnostic and therapeutic challenges.
  • [MeSH-major] Nerve Sheath Neoplasms / genetics. Neurofibroma / genetics. Neurofibromatosis 1 / genetics. Neurofibromin 1 / genetics
  • [MeSH-minor] Adult. Base Sequence. Comparative Genomic Hybridization. DNA Mutational Analysis. Disease Progression. Germ-Line Mutation. Humans. Loss of Heterozygosity. Male. Molecular Sequence Data


44. Pasmant E, Ortonne N, Rittié L, Laurendeau I, Lévy P, Lazar V, Parfait B, Leroy K, Dessen P, Valeyrie-Allanore L, Perbal B, Wolkenstein P, Vidaud M, Vidaud D, Bièche I: Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis. J Neuropathol Exp Neurol; 2010 Jan;69(1):60-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 1 patients with plexiform neurofibromas are at risk of developing malignant peripheral nerve sheath tumors.
  • Several CCN gene family members were dysregulated in neurofibromatosis type 1 tumorigenesis; the angiogenic gene CCN1/CYR61 was specifically upregulated in the plexiform neurofibromas; CCN4/WISP1 was upregulated, and CCN3/NOV and CCN5/WISP2 were downregulated in paired comparisons of plexiform neurofibroma and malignant peripheral nerve sheath tumor from the same patients.
  • [MeSH-minor] Adolescent. Adult. CCN Intercellular Signaling Proteins. Carcinogenicity Tests / methods. Cell Differentiation / genetics. Cells, Cultured. Cysteine-Rich Protein 61 / genetics. Cysteine-Rich Protein 61 / metabolism. Female. Gene Expression Profiling / methods. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Male. Middle Aged. Nephroblastoma Overexpressed Protein / genetics. Nephroblastoma Overexpressed Protein / metabolism. Oligonucleotide Array Sequence Analysis / methods. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. RNA, Messenger / metabolism. Repressor Proteins. Schwann Cells / physiology. Statistics, Nonparametric. Transcription Factors / genetics. Transcription Factors / metabolism. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010302.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCN Intercellular Signaling Proteins; 0 / CYR61 protein, human; 0 / Cysteine-Rich Protein 61; 0 / Intercellular Signaling Peptides and Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / NOV protein, human; 0 / Nephroblastoma Overexpressed Protein; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / WISP1 protein, human; 0 / WISP2 protein, human
  •  go-up   go-down


45. Rawal A, Yin Q, Roebuck M, Sinopidis C, Kalogrianitis S, Helliwell TR, Frostick S: Atypical and malignant peripheral nerve-sheath tumors of the brachial plexus: report of three cases and review of the literature. Microsurgery; 2006;26(2):80-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical and malignant peripheral nerve-sheath tumors of the brachial plexus: report of three cases and review of the literature.
  • Tumor involvement of the brachial plexus is uncommon.
  • Malignant peripheral nerve-sheath tumors (MPNST) are rare at this site, arising spontaneously or in the context of NF-1.
  • MPNST are intermediate or high-grade sarcomas with a high risk of local and distant spread.
  • Approximately 50% of MPNST arise in patients with NF-1, and therefore these patients should be thoroughly investigated for any new symptoms or masses.
  • MPNST of the brachial plexus should be treated with an adequate wide local excision, with adjuvant high-dose radiotherapy pre- or postoperatively.
  • The role of chemotherapy in the treatment of MPNST is not clearly defined, but it may have some benefit in salvaging treatment failures.
  • [MeSH-major] Brachial Plexus. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Neurofibromatosis 1 / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538633.001).
  • [ISSN] 0738-1085
  • [Journal-full-title] Microsurgery
  • [ISO-abbreviation] Microsurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


46. Dang JD, Cohen PR: Segmental neurofibromatosis and malignancy. Skinmed; 2010 May-Jun;8(3):156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The malignancies include malignant peripheral nerve sheath tumor (3), malignant melanoma (2), breast cancer (1), colon cancer (1), gastric cancer (1), lung cancer (1), and Hodgkin lymphoma (1).
  • The most common malignancies in patients with segmental neurofibromatosis are derived from neural crest cells: malignant peripheral nerve sheath tumor and malignant melanoma.
  • [MeSH-minor] Adult. Aged. Cafe-au-Lait Spots / etiology. Cafe-au-Lait Spots / pathology. Female. Humans. Incidence. Male. Middle Aged. Neural Crest / cytology. Neural Crest / pathology. Risk

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137621.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


47. Matsuda E, Okabe K, Matsuoka T, Hirazawa K, Azuma T, Murakami T, Sugi K: [Lung metastasis of malignant peripheral nerve sheath tumor: report of a case]. Kyobu Geka; 2007 Sep;60(10):950-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung metastasis of malignant peripheral nerve sheath tumor: report of a case].
  • He had underwent extended radical tumorectomy for malignant peripheral nerve sheath tumor (MPNST) in left lower limb 33 months before.
  • Chest X-ray and computed tomography (CT) scan revealed solitary tumor on right S10.
  • Tumor was resected under thoracoscopic surgery.
  • Histological diagnosis was metastasis of MPNST.
  • MPNST with lung metastasis showing very poor prognosis.
  • Careful follow up is important for MPNST.
  • [MeSH-major] Lung Neoplasms / secondary. Nerve Sheath Neoplasms / secondary. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Neurofibromatosis 1 / complications. Prognosis. Survivors. Thoracoscopy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877020.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Izycka-Swieszewska E, Drogoszewska B, Filipowicz J, Szurowska E, Kaminski M, Jaskiewicz K: Epithelioid malignant peripheral nerve sheath tumor involving maxillary sinus. Neuropathology; 2005 Dec;25(4):341-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid malignant peripheral nerve sheath tumor involving maxillary sinus.
  • We present a case of epithelioid malignant peripheral nerve sheath tumor (MPNST) located in the maxillary sinus region in a young man.
  • Histologically, the neoplasm had a predominant epithelioid component.
  • An appropriate immunohistochemical panel was essential for the final diagnosis of this epithelioid malignant tumor, with the location rather unusual for MPNST.
  • [MeSH-major] Maxillary Sinus Neoplasms / pathology. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma / pathology. Diagnosis, Differential. Fatal Outcome. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382783.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


49. Aoki M, Nabeshima K, Nishio J, Ishiguro M, Fujita C, Koga K, Hamasaki M, Kaneko Y, Iwasaki H: Establishment of three malignant peripheral nerve sheath tumor cell lines, FU-SFT8611, 8710 and 9817: conventional and molecular cytogenetic characterization. Int J Oncol; 2006 Dec;29(6):1421-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of three malignant peripheral nerve sheath tumor cell lines, FU-SFT8611, 8710 and 9817: conventional and molecular cytogenetic characterization.
  • Malignant peripheral nerve sheath tumor (MPNST) is a rare malignant tumor, for which only a few cultured cell lines are available to date.
  • In the present study, we established three new MPNST cell lines, FU-SFT8611, FU-SFT8710 and FU-SFT9817, from a 40-year-old Japanese man without neurofibromatosis 1 (NF1), a 43-year-old Japanese woman with NF1, and a 61-year-old Japanese woman without NF1, respectively.
  • These newly established cell lines provide a valuable resource for biological and pathological investigations into new treatment regimes for MPNST.
  • [MeSH-major] Cell Line, Tumor. Nerve Sheath Neoplasms / genetics
  • [MeSH-minor] Adult. Animals. Cell Growth Processes / physiology. Cytogenetic Analysis / methods. Female. Humans. Immunohistochemistry. Karyotyping. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Mice, SCID. Middle Aged. Neoplasm Transplantation. Neurofibromatosis 1 / genetics. Neurofibromatosis 1 / pathology. Nucleic Acid Hybridization. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088980.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


50. Nepka C, Karadana M, Karasavvidou F, Barbanis S, Kalodimos G, Koukoulis G: Fine needle aspiration cytology of a primary malignant peripheral nerve sheath tumor arising in the parotid gland: a case report. Acta Cytol; 2009 Jul-Aug;53(4):423-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of a primary malignant peripheral nerve sheath tumor arising in the parotid gland: a case report.
  • BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST) is an uncommon mesenchymal neoplasm showing nerve sheath differentiation, usually arising in large nerves of the trunk and extremities.
  • We describe fine needle aspiration (FNA) findings in a case of MPNST in the parotid gland.
  • Smears were cellular, with clusters of tightly packed spindle or oval cells arranged in a storiform or whorled pattern, showing clearly malignant features.
  • The background contained abundant necrotic material with dispersed malignant nuclei.
  • Cytologic diagnosis was positive for malignant cells consistent with a spindle cell sarcoma, with morphologic features compatible to neural differentiation, confirmed by histologic examination.
  • CONCLUSION: This case illustrates that attention to moiphologic criteria suggestive of nerve sheath phenotype supported by immunocytochemical data is extremely helpful and reliable in the diagnostic approach to MPNSTs, even in rare locations.
  • [MeSH-major] Biopsy, Fine-Needle. Nerve Sheath Neoplasms / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2010 Sep-Oct;54(5 Suppl):1073-4 [21053609.001]
  • (PMID = 19697728.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Miyake M, Tateishi U, Maeda T, Arai Y, Seki K, Hasegawa T, Sugimura K: A case of ganglioneuroma presenting abnormal FDG uptake. Ann Nucl Med; 2006 Jun;20(5):357-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 26-year-old woman presented to the hospital with a slowly growing abdominal tumor without symptoms.
  • However, a second primary malignant tumor, such as malignant peripheral nerve sheath tumor arising in ganglioneuroma, could not be ruled out.
  • Pathological investigation may be needed to differentiate ganglioneuroma from other malignant tumors and, therefore, FDG-PET/CT findings can be helpful for biopsy planning.
  • [MeSH-minor] Adult. Female. Humans. Radiopharmaceuticals / pharmacokinetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878708.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


52. Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever PE, Lim M, Conway SJ, Parada LF, Zhu Y, Morrison SJ: The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell; 2008 Feb;13(2):129-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis is caused by the loss of neurofibromin (Nf1), leading to peripheral nervous system (PNS) tumors, including neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs).
  • However, Nf1-deficient NCSCs did not persist postnatally in regions of the PNS that developed tumors and could not form tumors upon transplantation into adult nerves.
  • Adult P0a-Cre+Nf1(fl/-) mice developed neurofibromas, and Nf1(+/-)Ink4a/Arf(-/-) and Nf1/p53(+/-) mice developed MPNSTs, but NCSCs did not persist postnatally in affected locations in these mice.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6;129S2-Trp53<tm1Tyj> Nf1<tm1Tyj>/J (subscription/membership/fee required).
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.129S2-Nf1<tm1Tyj>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):117-28 [18242512.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):66-78 [11156606.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Histopathology. 2001 Sep;39(3):298-309 [11532041.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):86-91 [11544531.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4978-82 [12118376.001]
  • [Cites] Neuron. 2002 Aug 15;35(4):643-56 [12194865.001]
  • [Cites] Neuron. 2002 Aug 15;35(4):657-69 [12194866.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):75-9 [12469121.001]
  • [Cites] Neuron. 2003 Apr 10;38(1):17-31 [12691661.001]
  • [Cites] Science. 2003 Aug 15;301(5635):972-6 [12920301.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4132-8 [14519636.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Mol Cancer. 2004 Jul 15;3:20 [15255999.001]
  • [Cites] Nat Neurosci. 2004 Sep;7(9):930-8 [15322547.001]
  • [Cites] Development. 2004 Nov;131(22):5599-612 [15496445.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5435-9 [2142531.001]
  • [Cites] Development. 1990 May;109(1):91-103 [2209471.001]
  • [Cites] Histopathology. 1991 Jul;19(1):1-11 [1916682.001]
  • [Cites] Cell. 1992 Dec 11;71(6):973-85 [1458542.001]
  • [Cites] Nat Genet. 1994 Jul;7(3):353-61 [7920653.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Nature. 1994 Oct 27;371(6500):796-9 [7935840.001]
  • [Cites] Oncogene. 1995 Jul 20;11(2):325-35 [7624147.001]
  • [Cites] Cell. 1995 Sep 8;82(5):733-42 [7671302.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] Mol Cell Neurosci. 1997;8(5):336-50 [9073396.001]
  • [Cites] Curr Biol. 1998 Dec 3;8(24):1323-6 [9843687.001]
  • [Cites] Cell. 1999 Mar 5;96(5):737-49 [10089888.001]
  • [Cites] Development. 1999 Sep;126(17):3781-94 [10433908.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1082-93 [15517002.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jan;64(1):74-81 [15715087.001]
  • [Cites] J Neurosci. 2005 Jun 8;25(23):5584-94 [15944386.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1432-7 [15964994.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):557-64 [16069817.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Nat Rev Neurosci. 2005 Sep;6(9):671-82 [16136171.001]
  • [Cites] Development. 2005 Dec;132(24):5577-88 [16314489.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1005-15 [17158956.001]
  • [Cites] Dev Biol. 2007 Jul 15;307(2):340-55 [17540359.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2176-9 [10591653.001]
  • (PMID = 18242513.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL077342-04; United States / NINDS NIH HHS / NS / R01 NS040750; United States / NINDS NIH HHS / NS / R01 NS040750-06; United States / NINDS NIH HHS / NS / NS040750-08; United States / NINDS NIH HHS / NS / NS040750-07; United States / NINDS NIH HHS / NS / R01 NS040750-01; United States / NINDS NIH HHS / NS / R01 NS40750; United States / NINDS NIH HHS / NS / R01 NS040750-08; United States / NINDS NIH HHS / NS / NS040750-06; United States / NINDS NIH HHS / NS / R01 NS040750-07; United States / NHLBI NIH HHS / HL / R01 HL077342; United States / NHLBI NIH HHS / HL / T32 HL079995; United States / NHLBI NIH HHS / HL / HL077342-04; United States / NINDS NIH HHS / NS / NS040750-01; United States / NINDS NIH HHS / NS / F30 NS049761
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Neurofibromin 1; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS40133; NLM/ PMC2566828
  •  go-up   go-down


53. Amary MF, Berisha F, Bernardi Fdel C, Herbert A, James M, Reis-Filho JS, Fisher C, Nicholson AG, Tirabosco R, Diss TC, Flanagan AM: Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Mod Pathol; 2007 Apr;20(4):482-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma.
  • Synovial Sarcoma consistently harbors t(X;18) resulting in SS18-SSX1, SS18-SSX2 and rarely SS18-SSX4 fusion transcripts.
  • Of 328 cases included in our study, synovial sarcoma was either the primary diagnosis or was very high in the differential diagnosis in 134 cases: of these, amplifiable cDNA was obtained from 131.
  • SS18-SSX1 was present in 56 monophasic and 18 biphasic synovial sarcoma: SS18-SSX2 was detected in 41 monophasic and 11 biphasic synovial sarcoma.
  • Following clinical input, a diagnosis of mesothelioma was favored in one case, a sarcoma, not otherwise specified in another and a solitary fibrous tumor in the third case.
  • The possibility of a malignant peripheral nerve sheath tumor could not be excluded in the other two cases.
  • We concluded that the employment of a combination of molecular approaches is a powerful aid to diagnosing synovial sarcoma giving at least 96% sensitivity and 100% specificity but results must be interpreted in the light of other modalities such as clinical findings and immunohistochemical data.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins / metabolism. Repressor Proteins / metabolism. Sarcoma, Synovial / metabolism. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Female. Formaldehyde. Humans. Immunohistochemistry. Male. Middle Aged. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Paraffin Embedding. RNA, Messenger / metabolism. Recombinant Fusion Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tissue Fixation

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334349.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins; 0 / Repressor Proteins; 0 / SS18 protein, human; 0 / SYT-SSX fusion protein; 164289-47-8 / synovial sarcoma X breakpoint proteins; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


54. Minovi A, Basten O, Hunter B, Draf W, Bockmühl U: Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review. Head Neck; 2007 May;29(5):439-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review.
  • BACKGROUND: This study analyzes the management and outcomes of a series of 10 malignant peripheral nerve sheath tumors (MPNST) of the head and neck.
  • METHODS: From 1984 to 2004, 10 patients underwent surgical treatment of a MPNST.
  • RESULTS: Eight tumors were located at the lateral skull base; 2 involved the vagus nerve in isolation.
  • Negative prognostic indicators were advanced tumor stage, early recurrence, and presumably also the presence of von Recklinghausen's disease.
  • CONCLUSIONS: Although rare, MPNST is one of the most aggressive tumors in the head and neck area.
  • Complete tumor removal is the mainstay of treatment and most important prognostic factor of MPNST.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 17163467.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


55. Lee CC, Yen YS, Pan DH, Chung WY, Wu HM, Guo WY, Chen MT, Liu KD, Shih YH: Delayed microsurgery for vestibular schwannoma after gamma knife radiosurgery. J Neurooncol; 2010 Jun;98(2):203-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed microsurgery for vestibular schwannoma after gamma knife radiosurgery.
  • However, on rare occasions, some cases have needed traditional microsurgery to remove the tumor several months or years after radiosurgery.
  • The mean size of the tumor during GKS was 10.4 ml (range 2.3-23.5 ml).
  • The indications of microsurgery included adverse radiation effect with peri-focal edema, tumor enlargement, and cyst enlargement.
  • Although the perifocal edema could lead to more difficulty in surgery than in typically performed operations for schwannoma, subtotal resection was achieved in all patients.
  • The histology showed benign tumor in five patients, malignant peripheral nerve sheath tumor in one, and necrotic tissue in one.
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted / methods. Ki-67 Antigen / metabolism. Longitudinal Studies. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. S100 Proteins / metabolism. Severity of Illness Index. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 2007 Mar;149(3):313-6; discussion 316-7 [17273886.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):109-10 [14693854.001]
  • [Cites] J Neurosurg. 2006 Oct;105(4):576-80 [17044561.001]
  • [Cites] J Neurosurg. 1992 May;76(5):874-7 [1564550.001]
  • [Cites] J Neurosurg. 1990 Dec;73(6):946-50 [2230979.001]
  • [Cites] J Korean Med Sci. 2001 Dec;16(6):817-21 [11748371.001]
  • [Cites] Acta Neurochir (Wien). 2002 Jul;144(7):671-6; discussion 676-7 [12181700.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):469-81; discussion 481-2 [9055285.001]
  • [Cites] Am J Surg Pathol. 2009 Mar;33(3):325-38 [19065105.001]
  • [Cites] Acta Otolaryngol Suppl. 2000;543:11-3 [10908962.001]
  • [Cites] Acta Neuropathol. 1987;74(1):92-6 [3499046.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:103-11 [9032850.001]
  • [Cites] J Laryngol Otol. 2000 Dec;114(12):935-9 [11177361.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):653-8 [9761063.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):908-12 [12810777.001]
  • [Cites] Neurosurgery. 2008 May;62(5):E1164-5; discussion E1165 [18580785.001]
  • [Cites] Am J Otol. 1995 May;16(3):315-9; discussion 319-21 [8588625.001]
  • [Cites] Arch Pathol Lab Med. 1983 Jun;107(6):293-7 [6687792.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):7-13 [11147901.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):580-90 [15952200.001]
  • [Cites] J Neurosurg. 2000 May;92(5):745-59 [10794287.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(6):695-9 [8836284.001]
  • [Cites] J Laryngol Otol. 1994 May;108(5):375-9 [8035113.001]
  • [Cites] N Engl J Med. 1998 Nov 12;339(20):1426-33 [9811917.001]
  • [Cites] Clin Neurosurg. 1993;40:498-535 [8111998.001]
  • [Cites] J Neurosurg. 1998 Dec;89(6):949-55 [9833821.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):422-5 [1993907.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):518-21 [11565878.001]
  • [Cites] J Neurosurg. 2005 Jan;102(s_supplement):87-97 [28306447.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):309-10 [12147377.001]
  • (PMID = 20405307.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / S100 Proteins
  •  go-up   go-down


56. Moon SJ, Lee JK, Seo BR, Kim JH, Kim SH, Lee KH, Lee MC: An intraosseous malignant peripheral nerve sheath tumor of the cervical spine: a case report and review of the literature. Spine (Phila Pa 1976); 2008 Sep 1;33(19):E712-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intraosseous malignant peripheral nerve sheath tumor of the cervical spine: a case report and review of the literature.
  • OBJECTIVES: To report a rare case of intraosseous malignant peripheral nerve sheath tumors (MPNST), and review the pertinent medical literature.
  • SUMMARY OF BACKGROUND DATA: The spinal MPNST that develops from spinal nerve roots and secondary bony erosion is well-known entity.
  • Complete excision of the tumor and posterior stabilization were performed through a posterior approach.
  • The tumor was noted to originate from the posterior element of C7.
  • RESULTS: The histopathology was diagnostic for a MPNST.
  • CONCLUSION: We report an intraosseous MPNST of the cervical spine.
  • MPNST should be added to the differential diagnosis of primary bone tumors causing spinal cord compression.
  • [MeSH-major] Cervical Vertebrae / pathology. Nerve Sheath Neoplasms / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Humans. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. S100 Proteins / metabolism. Spinal Cord Compression / etiology. Spinal Cord Compression / pathology. Vimentin / metabolism

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758353.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Ki-67 Antigen; 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


57. Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, Yamamoto H, Yokoyama R, Uchiumi T, Iwamoto Y, Kuwano M, Tsuneyoshi M: ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer; 2005 May 10;114(6):854-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The phenomenon of multidrug resistance (MDR) in various malignant neoplasms has been reported as being caused by one or multiple expressions of ATP-binding cassette (ABC) superfamily protein, including P-glycoprotein/multidrug resistance (MDR) 1 and the MDR protein (MRP) family.
  • In 86 cases of surgically resected soft tissue sarcoma, intrinsic mRNA levels of MDR1, MRP1, MRP2 and MRP3 were assessed using a quantitative reverse transcriptase-PCR (RT-PCR) method.
  • Among the various histologic types, malignant peripheral nerve sheath tumor (MPNST) showed significantly high levels of MDR1 (p=0.017) and MRP3 (p=0.0384) mRNA expression, compared to the other tumor types.
  • P-gp expression was significantly correlated with large tumor size (> or =5 cm, p=0.041) and high AJCC stage (stages III and IV) (p=0.0365).
  • Our results suggest that MDR1/P-gp expression may have an important role to play in tumor progression in the cases of soft tissue sarcoma, and p53 may be one of the active regulators of the MDR1 transcript.
  • In addition, the high levels of both MDR1 and MRP3 mRNA expression in MPNST may help to explain the poor response of this tumor to anticancer-drugs.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. ATP-Binding Cassette Transporters / genetics. Drug Resistance, Multiple. Gene Expression Regulation, Neoplastic. Genes, p53. Sarcoma / drug therapy. Sarcoma / genetics
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Drug Resistance, Neoplasm / genetics. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609299.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters
  •  go-up   go-down


58. Gonzalez LF, Lekovic GP, Eschbacher J, Coons S, Spetzler RF: A true malignant schwannoma of the eighth cranial nerve: case report. Neurosurgery; 2007 Aug;61(2):E421-2; discussion E422
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A true malignant schwannoma of the eighth cranial nerve: case report.
  • OBJECTIVE: The clinical presentation, pathology, treatment, and outcome of a 43-year-old woman with a malignant peripheral nerve sheath tumor arising from a benign schwannoma of the eighth cranial nerve are presented.
  • CLINICAL PRESENTATION: Initially, the tumor was debulked.
  • After finding malignant areas within the benign tumor, it was considered to be a malignant transformation of a previously benign tumor.
  • Postoperatively, the tumor bed was radiated for palliation.
  • [MeSH-major] Cranial Nerve Neoplasms / pathology. Neuroma, Acoustic / secondary. Vestibulocochlear Nerve / pathology
  • [MeSH-minor] Adult. Dura Mater / pathology. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Meningeal Neoplasms / secondary

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762727.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Nicklas BJ, Smith AD, Wolff RD, Johnson FA: Malignant peripheral nerve sheath tumor arising in association with the sural nerve. J Foot Ankle Surg; 2006 Jan-Feb;45(1):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor arising in association with the sural nerve.
  • Malignant peripheral nerve sheath tumor is a rare sarcoma of peripheral nerves found most often in deep soft tissue.
  • This aggressive tumor is difficult to diagnose clinically and must be surgically excised for therapy.
  • The authors present a case of a 39-year-old African American woman with malignant peripheral nerve sheath tumor in association with the sural nerve.
  • The tumor was surgically removed and sent for pathologic studies.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Soft Tissue Neoplasms / pathology. Sural Nerve / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399558.001).
  • [ISSN] 1067-2516
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Perrin GQ, Fishbein L, Thomson SA, Thomas SL, Stephens K, Garbern JY, DeVries GH, Yachnis AT, Wallace MR, Muir D: Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line. J Neurosci Res; 2007 May 1;85(6):1347-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line.
  • Plexiform neurofibromas are peripheral nerve sheath tumors that arise frequently in neurofibromatosis type 1 (NF1) and have a risk of malignant progression.
  • Past efforts to establish xenograft models for neurofibroma involved the implantation of tumor fragments or heterogeneous primary cultures, which rarely achieved significant tumor growth.
  • We report a practical and reproducible animal model of plexiform-like neurofibroma by xenograft of an immortal human NF1 tumor-derived Schwann cell line into the peripheral nerve of scid mice.
  • Localized intraneural injection of the cell line sNF94.3 produced consistent and slow growing tumors that infiltrated and disrupted the host nerve.
  • [MeSH-major] Cell Line, Tumor. Lung Neoplasms / pathology. Neurofibromatosis 1 / pathology. Schwann Cells / cytology
  • [MeSH-minor] Adult. Animals. Blotting, Western. Female. Humans. Mice. Mice, SCID. Neoplasm Transplantation / methods. Nerve Tissue Proteins / metabolism. Neurofibromin 1 / genetics. Transplantation, Heterologous / methods. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17335073.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32-CA09126-27
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Neurofibromin 1; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


61. Verdijk RM, den Bakker MA, Dubbink HJ, Hop WC, Dinjens WN, Kros JM: TP53 mutation analysis of malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol; 2010 Jan;69(1):16-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 mutation analysis of malignant peripheral nerve sheath tumors.
  • Mutations in TP53 underlie the development of malignant peripheral nerve sheath tumors (MPNSTs) in animal models, but there is controversy regarding the extent of TP53 mutations in human MPNSTs.
  • A minority of patients (n = 26, 30%) had neurofibromatosis type 1 (NF1); in these patients, the diagnosis of MPNST was made at younger ages (33 [SD, 3.6] years vs 49 [SD, 2.9] years in NF1 vs non-NF1; p = 0.003).
  • These results indicate that TP53 mutations are relatively rare in human MPNST and that they are not positively correlated with the presence of NF1.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Mutation / genetics. Nerve Sheath Neoplasms / genetics. Peripheral Nervous System Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Child. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Neurofibromatosis 1 / genetics. Retrospective Studies. Statistics, Nonparametric. Ubiquitin-Protein Ligases / metabolism. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010306.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


62. Grimm S, Chamberlain MC: Adult primary spinal cord tumors. Expert Rev Neurother; 2009 Oct;9(10):1487-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult primary spinal cord tumors.
  • Resective surgery can usually be accomplished with spinal ependymomas owing to separation of tumor from spinal cord and, when complete, require no further therapy.
  • Intradural extramedullary tumors are either peripheral nerve sheath tumors (neurofibromas or schwanommas) or meningiomas.
  • Radiotherapy is reserved for rare malignant variants and for patients in whom surgery is contraindicated.
  • Primary treatment is surgery in essentially all spinal cord tumors, and predictors of outcome include preoperative functional status, histological grade of tumor and extent of surgical resection.
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Neurosurgical Procedures. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19831838.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 82
  •  go-up   go-down


63. Gladdy RA, Qin LX, Moraco N, Edgar MA, Antonescu CR, Alektiar KM, Brennan MF, Singer S: Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol; 2010 Apr 20;28(12):2064-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A matched-cohort analysis was performed for radiation-associated and sporadic malignant fibrous histiocytoma (MFH).
  • DSS was significantly worse in primary RAS malignant peripheral nerve sheath tumors (MPNSTs) compared with unmatched sporadic MPNSTs (P = .001).
  • CONCLUSION Histologic type, margin status, and tumor size are the most important independent predictors of DSS in patients with RASs.
  • DSS in patients with primary RAS is significantly worse compared with sporadic STS independent of sarcoma histologic type.


64. Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC: Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res; 2010 Jan 15;16(2):750-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Ixabepilone is a microtubule-stabilizing agent with activity in adult solid tumors and in pediatric tumor xenograft models that are resistant to paclitaxel.
  • This study aimed to determine the response rate to ixabepilone in six solid tumor strata in children and young adults.
  • EXPERIMENTAL DESIGN: We conducted a phase II trial of ixabepilone (8 mg/m(2)/dose for 5 days every 21 days) using a two-stage design in taxane-naïve children and young adults with treatment-refractory, measurable rhabdomyosarcoma, Ewing sarcoma family tumors, osteosarcoma, synovial sarcoma, or malignant peripheral nerve sheath tumor, neuroblastoma, and Wilms tumor.
  • Seven patients received >or=3 cycles, and two had prolonged stable disease (Wilms' tumor, 38 cycles; synovial sarcoma, 8 cycles).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Ixabepilone .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8 [16203787.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):277-81 [11464982.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1866-73 [12721265.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):2015-25 [15143095.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2324-9 [7902425.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1538-43 [9193350.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):733-7 [10213206.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2726-34 [15837987.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1821-8 [16532433.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3421-7 [17606971.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3415-20 [17606972.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3399-406 [17606975.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1548-53 [17761711.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1207-23 [19088324.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):550-6 [19075272.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1429-37 [11350914.001]
  • (PMID = 20068084.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA 98543; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / U10 CA098543-08; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098413-08; None / None / / U10 CA098413-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epothilones; K27005NP0A / ixabepilone
  • [Other-IDs] NLM/ NIHMS160304; NLM/ PMC3086796
  •  go-up   go-down


65. Katenkamp K, Katenkamp D: [Low-malignant peripheral nerve sheath tumors of nasal and sinonasal mucous membranes]. Pathologe; 2005 Mar;26(2):90-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low-malignant peripheral nerve sheath tumors of nasal and sinonasal mucous membranes].
  • Sinonasal malignant peripheral nerve sheath tumors (MPNST) are infrequent neoplasms.
  • 16 cases of low-malignant MPNST in this localization were retrieved from the files of soft tissue tumors established in Jena.
  • The importance of an only partial immunostaining by S100 protein antibodies for diagnosis and differential diagnostic discrimination to benign peripheral nerve sheath tumors (schwannomas and neurofibromas) is explained.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. S100 Proteins / analysis. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2000 Jan;190(1):31-8 [10640989.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1337-45 [14508395.001]
  • [Cites] Mod Pathol. 1997 Aug;10(8):777-84 [9267819.001]
  • [Cites] Ann Diagn Pathol. 2000 Oct;4(5):303-7 [11073336.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1089-101 [1515984.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(5):401-5 [8116230.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1196-9 [12946223.001]
  • [Cites] Histopathology. 2000 May;36(5):387-402 [10792480.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1109-19 [7850709.001]
  • [Cites] Virchows Arch. 1995;427(1):19-26 [7551341.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1499-505 [10584703.001]
  • [Cites] Neurosurg Rev. 1998;21(1):58-61 [9584288.001]
  • [Cites] Arq Neuropsiquiatr. 2001 Jun;59(2-B):421-3 [11460191.001]
  • [Cites] Am J Clin Pathol. 1987 Apr;87(4):425-33 [2435144.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1443-9 [9414187.001]
  • [Cites] Am J Otolaryngol. 2001 May-Jun;22(3):215-8 [11351293.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):737-49 [12766577.001]
  • (PMID = 15657686.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


66. Bahrami A, Folpe AL: Adult-type fibrosarcoma: A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. Am J Surg Pathol; 2010 Oct;34(10):1504-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult-type fibrosarcoma: A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period.
  • Adult-type fibrosarcoma (FS) was once considered the most common adult sarcoma, but is now considered a diagnosis of exclusion.
  • One hundred ninety-five cases diagnosed as adult FS in somatic soft tissue were retrieved from our institutional archives for the period 1960 to 2008.
  • Non-FS (137 cases) were reclassified as: undifferentiated pleomorphic sarcoma (32 cases), SS (21 cases), solitary fibrous tumor (14 cases), myxofibrosarcoma (11 cases), malignant peripheral nerve sheath tumor (8 cases), FS dermatofibrosarcoma protuberans, and desmoplastic melanoma (4 cases each), low-grade fibromyxoid sarcoma, sarcomatoid carcinoma, desmoid-type fibromatosis, rhabdomyosarcoma, myofibroblastic sarcoma, spindle-cell liposarcoma (3 cases each), sclerosing epithelioid FS, fibroma-like epithelioid sarcoma, leiomyosarcoma, cellular fibrous histiocytoma (2 cases each), and others (17 cases).
  • Exclusive of undifferentiated pleomorphic sarcoma, the distinction of which from FS is subjective, 64% of putative FS were reclassified, most commonly as monophasic SS and solitary fibrous tumor.
  • We conclude that true FS is exceedingly rare, accounting for <1% of approximately 10,000 adult soft tissue sarcomas seen at our institution during this time period, and should be diagnosed with great caution.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Minnesota / epidemiology. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Repressor Proteins / genetics. Repressor Proteins / metabolism. Young Adult


67. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, Sloan JA, Atherton P, Edmonson JH, Erlichman C, Randlev B, Wang Q, Freeman S, Rubin J: Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther; 2005 Mar;12(5):437-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We, therefore, undertook a phase I/II study of ONYX-015, days 1-5 every month administered intratumorally under radiographic guidance, in combination with MAP (mitomycin-C, doxorubicin, cisplatin) chemotherapy in patients with advanced sarcoma.
  • Sarcoma histologies were gastrointestinal stromal tumors (GIST, two patients), leiomyosarcoma (two patients), liposarcoma (one patient), and malignant peripheral nerve sheath tumor (1 patient).
  • ONYX-015 viral DNA was detected by quantitative PCR in the plasma of 5/6 patients on day 5 of the first cycle, and up to day 12 (7 days after the last viral dose) in one patient who had extended sampling for viral kinetics performed, suggesting viral replication in sarcoma tissue.
  • Detection of viral DNA in post treatment tumor specimens by ISH and detection of the ONYX-015 genome in the peripheral blood by quantitative PCR, up to 7 days after the last viral dose provide evidence for adenoviral replication.
  • [MeSH-major] Adenoviridae. Antineoplastic Agents / administration & dosage. Genetic Therapy / methods. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Viral / blood. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. DNA, Viral / analysis. DNA, Viral / blood. Doxorubicin / administration & dosage. Female. Humans. In Situ Hybridization. Injections, Intralesional. Male. Middle Aged. Mitomycin / administration & dosage. Viral Vaccines. Virus Replication

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15647767.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 84388; United States / NCI NIH HHS / CA / U01CA 69912
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antineoplastic Agents; 0 / DNA, Viral; 0 / ONYX015; 0 / Viral Vaccines; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; MAP protocol
  •  go-up   go-down


68. Miura T, Yamada Y, Muramaki M, Tanaka K, Hara I, Fujisawa M: [A case of retroperitoneal malignant peripheral nerve sheath tumor in a patient with neurofibromatosis]. Hinyokika Kiyo; 2006 Mar;52(3):207-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal malignant peripheral nerve sheath tumor in a patient with neurofibromatosis].
  • We report a case of retroperitoneal malignant peripheral nerve sheath tumor (MPNST) in a patient with neurofibromatosis 1.
  • We performed complete resection of the tumor, confirming the margin status by frozen section examination intraoperatively.
  • The histopathological examination revealed MPNST.
  • [MeSH-major] Nerve Sheath Neoplasms / surgery. Neurofibromatosis 1 / complications. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617875.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Dozois EJ, Wall JC, Spinner RJ, Jacofsky DJ, Yaszemski MJ, Sim FH, Moran SL, Cima RR, Larson DR, Haddock MG, Okuno SH, Larson DW: Neurogenic tumors of the pelvis: clinicopathologic features and surgical outcomes using a multidisciplinary team. Ann Surg Oncol; 2009 Apr;16(4):1010-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurogenic tumors of the pelvis: clinicopathologic features and surgical outcomes using a multidisciplinary team.
  • BACKGROUND: Few data exist regarding the outcomes in patients undergoing surgery for pelvic tumors of neurogenic origin.
  • Our aim was to characterize the clinical and pathologic features of pelvic neurogenic tumors and assess surgical outcomes.
  • METHODS: All patients who underwent operations for pelvic neurogenic tumors at our institution between 1956 and 2004 were identified.
  • Malignant lesions were found in 43 patients (48%).
  • Schwannomas were the most common benign tumor (61%) and malignant peripheral nerve sheath tumors the most common malignant lesion (81%).
  • Median tumor size was 9.5 cm (range 0.8-32 cm).
  • Malignant tumors had histopathologic evidence of infiltration of surrounding structures in 49% of cases.
  • Intralesional resection was the most common surgical technique for both benign and malignant tumors.
  • Adjuvant therapy was given to 91% of the patients with malignant disease.
  • Five-year local recurrence rates for benign and malignant lesions were 35.9% and 35.0%, respectively.
  • Distant recurrence for malignant lesions was 65.1% at 5 years.
  • Five-year disease-free survival for malignant tumors was 25.9%.
  • CONCLUSION: Pelvic neurogenic tumors occurring in young patients may be large when detected and present with nonspecific symptoms.
  • Benign and malignant tumors had a high local recurrence rate and survival for malignant tumors was poor.
  • [MeSH-major] Neoplasms, Nerve Tissue / pathology. Neoplasms, Nerve Tissue / surgery. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Patient Care Team. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194756.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Martinez Devesa P, Mitchell TE, Scott I, Moffat DA: Malignant peripheral nerve sheath tumors of the head and neck: two cases and a review of the literature. Ear Nose Throat J; 2006 Jun;85(6):392-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors of the head and neck: two cases and a review of the literature.
  • Malignant peripheral nerve sheath tumors are uncommon lesions that occasionally affect the head and neck.
  • One tumor involved the parotid gland and resulted in erosion of the temporal bone, and the other affected the lower lip.
  • A rapid diagnosis has significant implications for management because of the tumor's potential for aggressive behavior and its high rate of recurrence.
  • [MeSH-major] Lip Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Angiography. Hearing Loss, Sensorineural / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Parotid Gland / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866118.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


71. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, Tamiya S, Tateishi N, Iwamoto Y, Tsuneyoshi M: DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol; 2006 Jan;19(1):106-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aberrant methylation of promoter CpG islands is known to be a major inactivation mechanism of tumor-related genes.
  • To determine the clinicopathological significance of gene promoter methylation in soft tissue sarcomas, we examined the promoter methylation status of 10 tumor-related genes in 65 soft tissue sarcomas and 19 adjacent non-neoplastic tissues by methylation-specific PCR.
  • The methylation frequencies of tumor-related genes tested in soft tissue sarcomas were 17 (26%) for RASSF1A, 11 (17%) for DAP kinase, 10 (15%) for MGMT, nine (14%) for GSTP1, eight (12%) for PTEN, six (9%) for p16 and hMLH1, five (8%) for hMSH2, two (3%) for p14, and one (2%) for RB.
  • All those cases of soft tissue sarcoma that had MGMT methylation, with the exception of one case of malignant peripheral nerve sheath tumor, showed large tumor size (> or = 10 cm) or recurrence.
  • In conclusion, although methylation of tumor-related genes was a relatively rare event in soft tissue sarcomas, methylation was tumor-specific.
  • Of 10 tumor-related genes, cases with MGMT methylation had a tendency to be aggressive behavior.
  • Although our findings need to be extending to a large series, promoter methylation of tumor-related genes is likely to have an association with the pathogenesis of soft tissue sarcomas.
  • Furthermore, MGMT methylation may be associated with tumor aggressiveness and the inactivation of MGMT gene.
  • [MeSH-major] Biomarkers, Tumor / genetics. DNA Methylation. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Carrier Proteins / genetics. Child. Child, Preschool. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Death-Associated Protein Kinases. Female. Glutathione S-Transferase pi / genetics. Humans. Immunohistochemistry. Infant. Male. Middle Aged. MutS Homolog 2 Protein / genetics. Nuclear Proteins / genetics. O(6)-Methylguanine-DNA Methyltransferase / analysis. O(6)-Methylguanine-DNA Methyltransferase / genetics. PTEN Phosphohydrolase / genetics. Polymerase Chain Reaction / methods. Promoter Regions, Genetic / genetics. Retinoblastoma Protein / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258501.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


72. Bredella MA, Torriani M, Hornicek F, Ouellette HA, Plamer WE, Williams Z, Fischman AJ, Plotkin SR: Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol; 2007 Oct;189(4):928-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of our study was to investigate the use of PET in the detection of malignant peripheral nerve sheath tumors (MPNSTs) in patients with neurofibromatosis type 1 (NF1).
  • MATERIALS AND METHODS: Forty-five patients with NF1 who underwent whole-body PET for suspected MPNST based on clinical symptoms or radiologic examinations were retrospectively evaluated.
  • PET may improve preoperative tumor staging by detecting metastases or second primary tumors, which often are present in patients with NF1.
  • [MeSH-major] Fluorodeoxyglucose F18. Methionine / deficiency. Neurofibromatosis 1 / radionuclide imaging. Peripheral Nervous System Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon Isotopes. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Whole Body Imaging / methods

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885067.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AE28F7PNPL / Methionine
  •  go-up   go-down


73. Kellogg A, Watson WJ: Malignant schwannoma in pregnancy: a case report and literature review. Am J Perinatol; 2010 Mar;27(3):201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant schwannoma in pregnancy: a case report and literature review.
  • Malignant peripheral nerve sheath tumors in pregnancy are an uncommon finding.
  • Evaluation revealed a large chest mass, biopsy proven to be a malignant schwannoma.
  • This malignant peripheral nerve sheath tumor, discovered at 26 weeks' gestation, grew so rapidly that delivery was necessary at 30 weeks' gestation.
  • [MeSH-major] Lung Neoplasms / pathology. Neoplasms, Second Primary / pathology. Neurilemmoma / pathology. Neurofibromatosis 1 / diagnosis. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Cesarean Section. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Pregnancy. Pregnancy Outcome. Prenatal Care / methods

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Thieme Medical Publishers.
  • (PMID = 19688672.001).
  • [ISSN] 1098-8785
  • [Journal-full-title] American journal of perinatology
  • [ISO-abbreviation] Am J Perinatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


74. Mott RT, Goodman BK, Burchette JL, Cummings TJ: Loss of chromosome 13 in a case of soft tissue perineurioma. Clin Neuropathol; 2005 Mar-Apr;24(2):69-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue perineuriomas are rare mesenchymal tumors that are derived from perineurial cells of the peripheral nerve sheath.
  • Histologically, the tumor was composed of a diffuse to fascicular arrangement of spindle cells with bland, elongated nuclei with long, thin, tapering cytoplasmic processes.
  • Although never described in this group of neoplasms, loss of chromosome 13 has been identified in a large number of other soft tissue tumors, particularly sarcomas and malignant peripheral nerve sheath tumors.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 13 / genetics. Nerve Sheath Neoplasms / genetics. Soft Tissue Neoplasms / genetics. Thigh
  • [MeSH-minor] Adult. Female. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803806.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 65
  •  go-up   go-down


75. Naikmasur VG, Guttal KS, Kaveriappa S, Datta KS: Rapidly progressing soft tissue mass of the anterior mandibular region. Malignant peripheral nerve sheath tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 May;107(5):607-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly progressing soft tissue mass of the anterior mandibular region. Malignant peripheral nerve sheath tumor.
  • [MeSH-major] Mandibular Neoplasms / pathology. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans. Terminology as Topic

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201222.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC: Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer; 2010 Jan 15;116(2):451-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
  • BACKGROUND: Correct pretreatment classification is critical for optimizing diagnosis and treatment of patients with peripheral nerve sheath tumors (PNSTs).
  • The aim of this study was to evaluate whether F18-fluorodeoxyglucose positron emission tomography (FDG PET) can differentiate malignant (MPNST) from benign PNSTs.
  • METHODS: Thirty-four adult patients presenting with PNST who underwent a presurgical FDG PET/computed tomography (CT) scan between February 2005 and November 2008 were included in the study.
  • Tumors were characterized histologically, by FDG maximum standardized uptake value (SUV(max) [g/mL]), and by CT size (tumor maximal diameter [cm]).
  • The accuracy of FDG PET for differentiating MPNSTs from benign PNSTs (neurofibroma and schwannoma) was evaluated by receiver operating characteristic (ROC) curve analysis.
  • SUV(max) was significantly higher in MPNST compared with benign PNST (12.0 +/- 7.1 vs 3.4 +/- 1.8; P < .001).
  • By ROC curve analysis, SUV(max) reliably differentiated between benign and malignant PNSTs (area under the ROC curve of 0.97).
  • Given the difficulties in clinically evaluating PNST and in distinguishing benign PNST from MPNST, FDG PET imaging should be used for diagnostic intervention planning and for optimizing treatment strategies.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 2001 Oct;28(10):1541-51 [11685498.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2856-63 [19351756.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):542-6 [11914894.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):29-43 [12533638.001]
  • [Cites] Eur J Surg Oncol. 2003 Aug;29(6):536-41 [12875862.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:25S-35S [14736833.001]
  • [Cites] AJR Am J Roentgenol. 2004 Apr;182(4):971-4 [15039173.001]
  • [Cites] J Nucl Med. 2004 May;45(5):797-801 [15136629.001]
  • [Cites] Lab Invest. 1983 Sep;49(3):299-308 [6310227.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Ann Surg Oncol. 1995 Mar;2(2):126-31 [7728565.001]
  • [Cites] Med Phys. 1998 Oct;25(10):2046-53 [9800714.001]
  • [Cites] J Med Genet. 1999 Mar;36(3):197-203 [10204844.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1667-72 [15520069.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2270-5 [15484214.001]
  • [Cites] J Nucl Med. 2005 Apr;46(4):603-7 [15809482.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):15-22 [16311108.001]
  • [Cites] Nat Med. 2006 Jan;12(1):122-7 [16341243.001]
  • [Cites] Virchows Arch. 2006 Dec;449(6):673-81 [17103226.001]
  • [Cites] AJR Am J Roentgenol. 2007 Oct;189(4):928-35 [17885067.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):390-4 [17932395.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):353-7 [10675220.001]
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10):1509-17 [11083540.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3203-9 [11432887.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1336-40 [11585292.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):715-20 [18245531.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):340-9 [18286466.001]
  • [Cites] J Nucl Med. 2008 Jul;49(7):1038-46 [18552153.001]
  • [Cites] Oral Dis. 2008 Sep;14(6):510-3 [18826382.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 May;36(5):751-7 [19142634.001]
  • [ErratumIn] Cancer. 2010 Feb 1;116(3):775
  • (PMID = 19924789.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA086306; United States / NCI NIH HHS / CA / 5 P50 CA086306
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS324300; NLM/ PMC3188986
  •  go-up   go-down


77. Strom T, Kleinschmidt-Demasters BK, Donson A, Foreman NK, Lillehei KO: Rare nerve lesions of non-nerve sheath origin: a 17-year retrospective series. Arch Pathol Lab Med; 2009 Sep;133(9):1391-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare nerve lesions of non-nerve sheath origin: a 17-year retrospective series.
  • CONTEXT: Peripheral nerve masses are frequently encountered in surgical pathology practice.
  • However, once a peripheral nerve mass is determined not to be a nerve sheath neoplasm, differential diagnostic considerations drop off sharply.
  • OBJECTIVE: To review our experience with surgically resected nerve masses.
  • After elimination of common lesions (mostly nerve sheath tumors), 37 cases (8%) remained, almost all of which were of non-nerve sheath origin: for example, hemangioma, metastatic neuroendocrine pancreatic carcinoma, meningiomas invading nerve fascicles, and primary extrarenal rhabdoid tumor and Ewing sarcoma of nerve.
  • The gene expression pattern of an undifferentiated sarcoma, presenting as ropelike nerve enlargement, clustered with malignant peripheral nerve sheath neoplasms but not other sarcomas or neuroepithelial tumors.
  • CONCLUSIONS: Diverse benign and malignant conditions can affect peripheral nerve.
  • [MeSH-major] Hemangioma / pathology. Meningioma / pathology. Pancreatic Neoplasms / pathology. Peripheral Nervous System Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunoglobulin Heavy Chains / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722745.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


78. Terzic A, Bode B, Gratz KW, Stoeckli SJ: Prognostic factors for the malignant triton tumor of the head and neck. Head Neck; 2009 May;31(5):679-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for the malignant triton tumor of the head and neck.
  • BACKGROUND: Malignant triton tumors are rare neoplasias consisting of a malignant peripheral nerve sheath tumor with additional rhabdomyoblastic differentiation.
  • METHODS: From 1993 to 2005, 7 patients with a malignant triton tumor of the head and neck were treated at our institution.
  • CONCLUSION: Location of the primary tumor is a key factor for prognosis.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Nerve Sheath Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19283843.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


79. Friedrich RE, Derlin T, Hagel C: Atypical plexiform neurofibroma in NF1 with high standardised uptake value (SUV) in positron-emission tomography (PET) expressing podoplanin. In Vivo; 2010 Nov-Dec;24(6):871-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 19-year-old female with established neurofibromatosis type 1 (NF1) diagnosis and history of malignant peripheral nerve sheath tumour (MPNST) of the lower extremities showed a tumour of her right upper extremity with a maximum standardised uptake value (SUV) of 5.7 on positron emission/computerised tomography (PET/CT) scan.
  • Scattered nerve fibres were labelled with neurofilament antibodies within the tumour.
  • This atypical neurofibroma showed a high SUV on PET that is indicative for MPNST.
  • [MeSH-minor] Biomarkers, Tumor / biosynthesis. Female. Humans. Positron-Emission Tomography. Young Adult

  • Genetic Alliance. consumer health - Neurofibroma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21164047.001).
  • [ISSN] 1791-7549
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human
  •  go-up   go-down


80. Muehling BM, Toelkes S, Schelzig H, Barth TF, Sunder-Plassmann L: Tyrosine kinase expression in pulmonary metastases and paired primary tumors. Interact Cardiovasc Thorac Surg; 2010 Feb;10(2):228-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue specimen from 35 lung metastases of 33 patients with renal cell carcinoma (n=8), sarcoma (n=10), colorectal carcinoma (n=6), otolaryngologic carcinoma (OLC, n=4), testicular and endometrial cancer (n=1 each), malignant melanoma (n=1), adrenal cancer (n=2), malignant fibrous histiocytoma and malignant peripheral nerve sheath tumor (n=1 each) have been immunohistochemically tested for the expression of PDGFR alpha/beta, VEGFR and EGFR.
  • Our investigation of a pilot character represents a 'biomarker-based' analysis of pulmonary metastases of different primary tumors; we conclude that an immediate 'tumor profiling' at initial diagnosis should be considered in order to guide tumor therapy individually.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lung Neoplasms / enzymology. Lung Neoplasms / secondary. Protein-Tyrosine Kinases / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Angiogenesis Inhibitors / therapeutic use. Female. Humans. Immunohistochemistry. Male. Middle Aged. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / analysis. Receptor, Platelet-Derived Growth Factor alpha / analysis. Receptor, Platelet-Derived Growth Factor beta / analysis. Receptors, Vascular Endothelial Growth Factor / analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19948538.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


81. Liang YM, Li XH, Lü YL, Zhong M: [Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors]. Zhonghua Yi Xue Za Zhi; 2005 Jan 12;85(2):96-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors].
  • OBJECTIVE: To investigate the morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors, and to conclude the diagnostic and differential diagnostic criteria for these morphologically similar tumors.
  • 20 primary tumors (43.4%), including 3 cases of sarcomatoid carcinoma (6.5%), 11 of angiosarcoma (23.9%), 2 of epithelioid hemangioendothelioma (5%), 1 of spindle cell carcinoid (2.2%), and 3 of undifferentiated sarcoma (6.5%).
  • and 26 metastatic malignant tumors (56.5%), including 20 cases of gastrointestinal stromal tumors (GIST, 43.4%), 3 of leiomyosarcoma (6.5%), 2 of malignant peripheral never sheath tumor (4.3%), and 1 of meningeal hemangiopericytoma (2.2%), resected during operation or collected during imaging-mediated liver puncture underwent hematoxylin-eosin staining, SP staining, and EnVision immunohistochemical staining.
  • Most stromal tumor cases were CD117 positive, and existed the condition that the primary tumor was positive and the metastatic tumor was negative or vice versa or one part of specimen was positive but other part was negative.
  • Leiomyosarcoma was immunoreactive to smooth muscle specific antigen (SMA), malignant peripheral nerve sheath tumor was immunoreactive to S-100 protein and neurofilament (NF), and both were CD117 negative.
  • CONCLUSION: Primary angiosarcoma is the most common form of primary spindle cell tumor in liver, and metastatic GIST is predominant in hepatic metastatic spindle cell tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD31 / biosynthesis. Antigens, CD34 / biosynthesis. Biomarkers, Tumor. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774214.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers, Tumor
  •  go-up   go-down


82. Dawamneh MF, Amra NK, Amr SS: Low grade fibromyxoid sarcoma: report of a case with fine needle aspiration cytology and histologic correlation. Acta Cytol; 2006 Mar-Apr;50(2):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade fibromyxoid sarcoma: report of a case with fine needle aspiration cytology and histologic correlation.
  • BACKGROUND: Low grade fibromyxoid sarcoma has been fully described histologically; however, the fine needle aspiration (FNA) cytologic findings are scantily defined, and the distinction from other benign and malignant soft tissue tumors can be difficult.
  • The excised tumor was well circumscribed, focally infiltrating the surrounding muscles.
  • The tumor cells were spindly, with fusiform, uniform nuclei.
  • The tumor cells were positive for vimentin, alpha-1-antitrypsin and lysozyme and negative for S-100, actin, desmin and CD34.
  • CONCLUSION: Although low grade fibromyxoid sarcoma is a rare neoplasm, it should be recognized and distinguished from other soft tissue tumors because of its low malignant potential.
  • The definitive FNA cytologic diagnosis can be challenging but is possible if the tumor is adequately sampled, with multiple passes from different areas.
  • All spindle cell tumors with myxoid changes, such as myxoid liposarcoma, myxofibrosarcoma, cellular myxoma, myxoid leiomyosarcoma and peripheral nerve sheath tumors, should be considered in the differential diagnosis.
  • [MeSH-minor] Adult. Biopsy, Fine-Needle / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Sensitivity and Specificity. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16610692.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Hagel C, Zils U, Peiper M, Kluwe L, Gotthard S, Friedrich RE, Zurakowski D, von Deimling A, Mautner VF: Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol; 2007 Apr;82(2):187-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors.
  • The differences in the clinical course and histopathology of sporadic and neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) were investigated retrospectively.
  • In patients with the original histopathological data available (22 NF1 patients, 14 sporadic cases), NF1-associated MPNST showed a significantly higher cellularity compared to sporadic tumors (p<0.001) whereas sporadic MPNST featured a significantly higher pleomorphism (p<0.01).
  • Most importantly, while histopathological variables correlated with French Fédération Nationale des Centres de Lutte Contre le Cancer grading in sporadic MPNST, this was not the case for NF1-associated tumors.
  • The differences between NF1-associated and sporadic MPNST in regard to the clinical course and histopathology may reflect some fundamental differences in biology and pathomechanism of the two tumor groups.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Neurofibromatosis 1 / pathology. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Incidence. Male. Middle Aged. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1999 Dec;155(6):1879-84 [10595918.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Eur J Surg Oncol. 1999 Apr;25(2):190-3 [10218464.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Am J Med Genet. 2000 Aug 28;93(5):388-92 [10951462.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jan;64(1):74-81 [15715087.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):297-303 [15446585.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):57-61 [11438454.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):282-8 [8816583.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Neurosurg Clin N Am. 2004 Apr;15(2):203-16 [15177319.001]
  • [Cites] Arch Dermatol. 2001 Jul;137(7):908-13 [11453810.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1885-91 [10595919.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1253-65 [2119249.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 May;122(5):667-72 [10793343.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • (PMID = 17111191.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Miettinen M, Fetsch JF, Sobin LH, Lasota J: Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol; 2006 Jan;30(1):90-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five of 35 patients with follow-up died of metastatic disease; all of these had a tumor >5 cm, mitotic rate >5/50 HPFs, or both; three of these tumors were located in the duodenum.
  • Most patients with long-term follow-up enjoyed a good prognosis; 2 died of other NF1-associated tumors (malignant peripheral nerve sheath tumors, brain tumor).
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330947.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


85. Albayrak BS, Gorgulu A, Kose T: A case of intra-dural malignant peripheral nerve sheath tumor in thoracic spine associated with neurofibromatosis type 1. J Neurooncol; 2006 Jun;78(2):187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of intra-dural malignant peripheral nerve sheath tumor in thoracic spine associated with neurofibromatosis type 1.
  • Histopathological diagnosis was malignant peripheral nerve sheath tumor (MPNST), a rare sarcoma with a dismal prognosis.
  • Tumor recurred in its previous site with an adjacent apical mass in the left lung 7 weeks following initial surgery and repeat surgery was performed with complete removal of intra-dural tumor.
  • We report the first patient with intra-dural MPNST localized proximal to conus medullaris; in upper thoracic spine.
  • It must always be considered the possibility of a rare but a devastating tumor, MPNST beside schwannomas and neurofibromas in patients with NF1 when an intra-spinal mass is diagnosed.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Neurofibromatosis 1 / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Dura Mater / pathology. Humans. Male. Neoplasm Recurrence, Local / surgery. Thoracic Vertebrae. Treatment Outcome


86. Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, Tamura K, Iwasaki H: Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab Invest; 2007 Aug;87(8):767-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
  • Malignant peripheral nerve sheath tumor (MPNST) is rare, highly aggressive, resistant to radiochemotherapy, and associated with poor prognosis.
  • This study was designed to identify motogenic factor(s) involved in MPNST cell invasion and inhibitor(s) of such invasive activity.
  • We profiled the invasion-inducing activities of eight motogenic growth factors on two human MPNST cell lines, FU-SFT8611 and 9817, using in vitro Matrigel invasion assays.
  • Platelet-derived growth factor-BB (PDGF-BB) was identified as the most effective MPNST cell invasion-inducing factor.
  • Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) also stimulated invasion in one MPNST cell line.
  • Expressions of PDGF-BB and EGF receptors (PDGFR-beta and EGFR) mRNAs were detected more frequently and their proteins were expressed at higher levels in MPNST tissues than benign peripheral nerve sheath tumors (schwannomas and neurofibromas).
  • In both MPNST cell lines, PDGF-BB induced tyrosine phosphorylation of PDGFR-beta but not of PDGFR-alpha, and specific PDGFR-beta inhibition by small interfering RNA to the receptor inhibited PDGF-BB-stimulated MPNST cell invasion, suggesting the predominant role of PDGFR-beta.
  • No mutations were present in exons 12 and 18 of PDGFR-beta in both MPNST cell lines and 10 human MPNST tissues examined.
  • Our results indicated that PDGF-BB enhanced the invasive activity of MPNST cells through PDGFR phosphorylation and that imatinib inhibited such activity.
  • The results provide the ground for further assessment of the therapeutic potential of imatinib in suppressing the invasion and growth of MPNST.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Nerve Sheath Neoplasms / metabolism. Piperazines / pharmacology. Platelet-Derived Growth Factor / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Adult. Benzamides. Cell Line, Tumor. Female. Humans. Imatinib Mesylate. Intercellular Signaling Peptides and Proteins / pharmacology. Intercellular Signaling Peptides and Proteins / physiology. Male. Middle Aged. Mutation. Neoplasm Invasiveness. Phosphorylation. Proto-Oncogene Proteins c-sis. RNA, Messenger / metabolism. Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor beta / genetics. Receptor, Platelet-Derived Growth Factor beta / metabolism. Receptors, Growth Factor / genetics. Receptors, Growth Factor / metabolism

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558420.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Intercellular Signaling Peptides and Proteins; 0 / Piperazines; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / Receptors, Growth Factor; 0 / platelet-derived growth factor BB; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


87. Ferrone M, Perrone F, Tamborini E, Paneni MS, Fermeglia M, Suardi S, Pastore E, Delia D, Pierotti MA, Pricl S, Pilotti S: Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y). Mol Cancer Ther; 2006 Jun;5(6):1467-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a previous TP53 analysis carried out on sporadic and NF1-related malignant peripheral nerve sheath tumors, in two cases, we observed the occurrence of C238Y missense mutation, leading to p53 stabilization unexpectedly coupled with immunophenotypic MDM2 overexpression.
  • [MeSH-major] Models, Molecular. Mutation, Missense. Proto-Oncogene Proteins c-mdm2 / genetics. Tumor Suppressor Protein p53 / physiology
  • [MeSH-minor] Adult. Blotting, Southern. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Female. Gene Amplification / physiology. Humans. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Mutagenesis, Site-Directed. Nerve Sheath Neoplasms / metabolism. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / therapy. Phosphorylation. Protein Conformation

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818505.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


88. Fleshman R, Mayerson J, Wakely PE Jr: Fine-needle aspiration biopsy of high-grade sarcoma: a report of 107 cases. Cancer; 2007 Dec 25;111(6):491-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of high-grade sarcoma: a report of 107 cases.
  • BACKGROUND: To the authors' knowledge, few studies exist demonstrating the reliability of fine-needle aspiration (FNA) biopsy for high-grade sarcoma (HGS).
  • Fifty-four cases were diagnosed as HGS, not otherwise specified, 8 as myxofibrosarcoma, 8 as osteosarcoma, 5 as malignant peripheral nerve sheath tumor, 5 as leiomyosarcoma, 4 as Ewing sarcoma, 4 as liposarcoma, 2 as epithelioid sarcoma, and 1 as angiosarcoma.
  • Approximately 71% of patients presented with a primary tumor, 23% with disease recurrence, and 7% with metastasis.
  • [MeSH-major] Biopsy, Fine-Needle. Cytodiagnosis. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Bone Neoplasms / diagnosis. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Predictive Value of Tests. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941014.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


89. Thway K, Fisher C: Diffuse ganglioneuromatosis in small intestine associated with neurofibromatosis type 1. Ann Diagn Pathol; 2009 Feb;13(1):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of diffuse ganglioneuromatosis of the small bowel, found incidentally during surgery for a malignant peripheral nerve sheath tumor arising in the retroperitoneum in a 32-year-old man with neurofibromatosis type 1, and review previously reported cases.
  • [MeSH-major] Ganglioneuroma / pathology. Intestinal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Nerve Sheath Neoplasms / pathology. Neurofibromatosis 1 / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19118783.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


90. Murovic JA, Charles Cho S, Park J: Surgical strategies for managing foraminal nerve sheath tumors: the emerging role of CyberKnife ablation. Eur Spine J; 2010 Feb;19(2):242-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for managing foraminal nerve sheath tumors: the emerging role of CyberKnife ablation.
  • Sixteen Stanford University Medical Center (SUMC) patients with foraminal nerve sheath tumors had charts reviewed.
  • Parameters were evaluated for 16 foraminal nerve sheath tumors undergoing surgery, some with CyberKnife.
  • The malignant peripheral nerve sheath tumor (MPNST) had prior field-radiation and adds another case.
  • The MPNST had a hemi-laminotomy then laminectomy/total facetectomy/fusion, followed by CyberKnife.
  • Of 11 single-operation-peripheral nerve sheath tumors, the asymptomatic case remained stable, nine (92%) improved and one (9%) worsened.
  • The MPNST had presentation improvement after the first operation, worsened and after the second surgery and CyberKnife, the patient expired from tumor spread.
  • In conclusion, surgery is beneficial for pain relief and function preservation in foraminal nerve sheath tumors.
  • [MeSH-major] Laminectomy / methods. Nerve Sheath Neoplasms / surgery. Radiosurgery / methods. Spinal Neoplasms / surgery. Spinal Nerve Roots / surgery. Spine / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dura Mater / pathology. Dura Mater / radiography. Dura Mater / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Radiotherapy / methods. Retrospective Studies. Spinal Canal / pathology. Spinal Canal / surgery. Survival Rate. Thoracotomy / methods. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1995 Jun;82(6):917-23 [7760192.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):572-7 [7897516.001]
  • [Cites] Skeletal Radiol. 1995 Aug;24(6):458-61 [7481906.001]
  • [Cites] Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 [8727812.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):67-74; discussion 74-5 [8747953.001]
  • [Cites] J Neurosurg Spine. 2007 Dec;7(6):587-93 [18074682.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):294-300 [8869056.001]
  • [Cites] Clin Orthop Relat Res. 1996 Apr;(325):251-5 [8998885.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Apr;37(4):354-7 [9136563.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):813-20; discussion 820-2 [9316042.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):279-89; discussion 289-90 [9482178.001]
  • [Cites] J Neurosurg. 1998 May;88(5):898-902 [9576261.001]
  • [Cites] Eur J Cell Biol. 1998 Apr;75(4):321-30 [9628318.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):430-3 [10070446.001]
  • [Cites] Neuroradiology. 1999 Sep;41(9):625-9 [10525761.001]
  • [Cites] Surg Gynecol Obstet. 1952 Feb;94(2):161-72 [14901250.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):291-318 [15527097.001]
  • [Cites] Neurosurgery. 2005 Mar;56(3):510-5; discussion 510-5 [15730576.001]
  • [Cites] Ann Thorac Surg. 2005 Apr;79(4):1411-2 [15797097.001]
  • [Cites] Clin Neurol Neurosurg. 2005 Jun;107(4):318-24 [15885392.001]
  • [Cites] Neurology. 2005 Jun 14;64(11):1838-45 [15955931.001]
  • [Cites] Expert Rev Neurother. 2005 Jul;5(4):515-23 [16026235.001]
  • [Cites] J Neurosurg Spine. 2005 Jul;3(1):1-11 [16122015.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):53-61 [16087703.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4):674-85; discussion 674-85 [16575331.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 29;348(3):971-80 [16908010.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1485-92 [16797490.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Feb 1;25(3):286-91 [10703098.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):187-90 [10903595.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(10):1099-104; discussion 1104-5 [11129530.001]
  • [Cites] J Spinal Disord. 2001 Feb;14(1):79-83 [11242279.001]
  • [Cites] J Neurosurg. 2001 Apr;94(2 Suppl):210-5 [11302622.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] J Spinal Disord Tech. 2002 Dec;15(6):507-12 [12468979.001]
  • [Cites] J Neurosurg. 2003 Jul;99(1 Suppl):121-4 [12859072.001]
  • [Cites] Clin Anat. 2003 Sep;16(5):404-10 [12903062.001]
  • [Cites] Spine (Phila Pa 1976). 2004 Jan 1;29(1):E10-4 [14699292.001]
  • [Cites] Eur J Radiol. 2004 May;50(2):159-76 [15081130.001]
  • [Cites] Neurol India. 2004 Sep;52(3):319-24 [15472419.001]
  • [Cites] J Neurosurg. 1968 Mar;28(3):191-203 [5643912.001]
  • [Cites] J Bone Joint Surg Am. 1983 Sep;65(7):992-7 [6885878.001]
  • [Cites] Ann Thorac Surg. 1983 Oct;36(4):402-7 [6625735.001]
  • [Cites] J Neurosurg. 1984 Oct;61(4):686-90 [6590800.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;47(4):291-301 [6151310.001]
  • [Cites] Radiology. 1985 Apr;155(1):143-6 [3975392.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):276-82 [3392571.001]
  • [Cites] Brain. 1988 Dec;111 ( Pt 6):1355-81 [3145091.001]
  • [Cites] Ann Intern Med. 1990 Jul 1;113(1):39-52 [2112353.001]
  • [Cites] J Bone Joint Surg Br. 1990 Sep;72(5):904-7 [2211781.001]
  • [Cites] J Neurosurg. 1991 Feb;74(2):248-53 [1846409.001]
  • [Cites] Neurology. 1991 Dec;41(12):1923-7 [1745350.001]
  • [Cites] Neurochirurgie. 1991;37(6):388-93 [1780017.001]
  • [Cites] Am J Hum Genet. 1992 Sep;51(3):486-96 [1496982.001]
  • [Cites] Surg Neurol. 1993 Dec;40(6):504-7 [8235975.001]
  • [Cites] Neurosurg Rev. 1994;17(1):43-9 [8078608.001]
  • [Cites] Clin Neurosurg. 1994;41:204-23 [7842604.001]
  • [Cites] Ann Thorac Surg. 1995 Feb;59(2):469-72 [7847968.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):621-6 [7674010.001]
  • (PMID = 19798517.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2899818
  •  go-up   go-down


91. Detjen AK, Tinschert S, Kaufmann D, Algermissen B, Nürnberg P, Schuelke M: Analysis of mitochondrial DNA in discordant monozygotic twins with neurofibromatosis type 1. Twin Res Hum Genet; 2007 Jun;10(3):486-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phenotype variability is high ranging from merely several café-au-lait spots to malignant peripheral nerve sheath tumors or severe disfigurement through plexiform neurofibromas.
  • Because of their co-localization with the tumor suppressor protein neurofibromin, which is mutated in NF1, mitochondria were particular attractive candidates for investigation.
  • [MeSH-minor] Adolescent. Adult. Child. DNA Mutational Analysis. Female. Genes, Neurofibromatosis 1. Genotype. Humans. Male. Phenotype. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564507.001).
  • [ISSN] 1832-4274
  • [Journal-full-title] Twin research and human genetics : the official journal of the International Society for Twin Studies
  • [ISO-abbreviation] Twin Res Hum Genet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


92. Furniss D, Swan MC, Morritt DG, Lim J, Khanna T, Way BL, Athanasou NA, Giele H, Critchley P: A 10-year review of benign and malignant peripheral nerve sheath tumors in a single center: clinical and radiographic features can help to differentiate benign from malignant lesions. Plast Reconstr Surg; 2008 Feb;121(2):529-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 10-year review of benign and malignant peripheral nerve sheath tumors in a single center: clinical and radiographic features can help to differentiate benign from malignant lesions.
  • BACKGROUND: Malignant peripheral nerve sheath tumors are rare, and their aggressive nature mandates treatment in specialist centers.
  • In contrast, benign peripheral nerve sheath tumors are common and are treated by a variety of specialist surgeons, including plastic surgeons.
  • The authors aimed to detect features in the clinical presentation of peripheral nerve sheath tumors that point toward a diagnosis of malignant peripheral nerve sheath tumor and therefore prompt referral to a specialist center.
  • METHODS: All histologically diagnosed primary peripheral nerve sheath tumors from January of 1995 to December of 2004 were identified from histopathology records.
  • RESULTS: During the study period, 32 cases of malignant peripheral nerve sheath tumor in 30 patients were treated.
  • Factors in the clinical evaluation that significantly predicted the presence of malignant peripheral nerve sheath tumor included site, large size, depth in relation to the deep fascia, short duration of symptoms, and pain.
  • Interestingly, schwannomata were harder to distinguish from malignant peripheral nerve sheath tumors both clinically and radiologically.
  • CONCLUSIONS: The authors have reviewed their institutional experience of peripheral nerve sheath tumors over a 10-year period.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Neurilemmoma / diagnosis. Neurofibroma / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Time Factors

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300972.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


93. Lehnhardt M, Daigeler A, Homann HH, Hauser J, Langer S, Steinsträsser L, Soimaru C, Puls A, Steinau HU: [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases]. Chirurg; 2009 Apr;80(4):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The records of 603 patients with soft tissue tumors of the extremities were reviewed concerning mismatches in primary and definite diagnoses relating to entity, evaluation of primary or recurrent tumor specimens, and the diagnosing pathology institution.
  • Liposarcoma and malignant fibrous histiocytoma were the most often diagnosed subgroups at 24% and 22.6%, respectively.
  • In the eight most frequent sarcoma types, malignant peripheral nerve sheath tumors and leiomyosarcoma had the highest rates of false primary diagnosis, 78.4% and 74.2% of cases, respectively.
  • [MeSH-major] Cancer Care Facilities. Extremities / surgery. Hospitals, Special. Hospitals, University. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diagnostic Errors. Female. Germany. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / diagnosis. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Neoplasm Staging. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery. Radiotherapy, Adjuvant. Referral and Consultation. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Cancer Treat Res. 2004;120:43-63 [15217217.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):404-6 [3179848.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):48-61 [9990113.001]
  • [Cites] Curr Top Pathol. 1995;89:123-51 [7882706.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):451-62 [15509479.001]
  • [Cites] Pathol Res Pract. 1988 Nov;183(6):698-705 [2851775.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):77-86 [15188669.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):212-9 [10613171.001]
  • [Cites] Bull Cancer. 2001 Aug;88(8):765-73 [11578945.001]
  • [Cites] Curr Oncol Rep. 2006 Jul;8(4):305-9 [17254531.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):111-5 [11823981.001]
  • [Cites] Chirurg. 2007 Jan;78(1):62-4 [16786340.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):157-67 [11856592.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):237-46 [15056054.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):329-35 [10989631.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • (PMID = 18523742.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Batra PS, Lanza DC: Endoscopic power-assisted orbital exenteration. Am J Rhinol; 2005 May-Jun;19(3):297-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient with persistent cavernous sinus malignant peripheral nerve sheath tumor died 4 months after resection despite proton beam therapy.
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / surgery. Child. Eyelids / surgery. Female. Humans. Male. Middle Aged. Mucormycosis / surgery. Nerve Sheath Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery. Retrospective Studies. Sinusitis / microbiology. Sinusitis / surgery. Time Factors. Tomography, X-Ray Computed. Wound Healing

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16011138.001).
  • [ISSN] 1050-6586
  • [Journal-full-title] American journal of rhinology
  • [ISO-abbreviation] Am J Rhinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Jarkowski A 3rd: Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. Am J Health Syst Pharm; 2008 Dec 1;65(23):2229-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: A 24-year-old white man diagnosed with a malignant peripheral nerve sheath tumor initially in the late 1990s was admitted to the hospital for treatment of a recurrence of the tumor in the supra-clavicular region.
  • CONCLUSION: A 24-year-old patient treated with ifosfamide, carboplatin, and etoposide for a malignant peripheral nerve sheath tumor developed ifosfamide-induced neurotoxicity after the addition of aprepitant to a standard antiemetic regimen consisting of ondansetron and dexamethasone.
  • [MeSH-major] Antiemetics / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Ifosfamide / adverse effects. Morpholines / adverse effects. Nerve Sheath Neoplasms / secondary. Neurotoxicity Syndromes / etiology
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Dexamethasone / administration & dosage. Drug Therapy, Combination. Etoposide / administration & dosage. Humans. Male. Nausea / prevention & control

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020190.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Morpholines; 1NF15YR6UY / aprepitant; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


96. Karatzoglou P, Karagiannidis A, Kountouras J, Christofiridis CV, Karavalaki M, Zavos C, Gavalas E, Patsiaoura K, Vougiouklis N: Von Recklinghausen's disease associated with malignant peripheral nerve sheath thmor presenting with constipation and urinary retention: a case report and review of the literature. Anticancer Res; 2008 Sep-Oct;28(5B):3107-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Von Recklinghausen's disease associated with malignant peripheral nerve sheath thmor presenting with constipation and urinary retention: a case report and review of the literature.
  • A malignant peripheral nerve sheath tumor (MPNST) is a rare neoplasm arising from peripheral nerve sheaths.
  • We herein report the first case of MPNST originating from the left gluteal muscle region, diffusely extending into the adjacent small pelvis and perineum.
  • A computed tomography scan revealed a giant tumor which displaced the bladder and segments of the intestine.
  • The histopathological diagnosis was MPNST.
  • [MeSH-major] Constipation / etiology. Nerve Sheath Neoplasms / complications. Neurofibromatosis 1 / complications. Urinary Retention / etiology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Constipation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031965.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


97. Serizawa I, Kagei K, Kamada T, Imai R, Sugahara S, Okada T, Tsuji H, Ito H, Tsujii H: Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys; 2009 Nov 15;75(4):1105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the applicability of carbon ion radiotherapy (CIRT) for unresectable retroperitoneal sarcomas with regard to normal tissue morbidity and local tumor control.
  • METHODS AND MATERIALS: From May 1997 to February 2006, 24 patients (17 male and 7 female) with unresectable retroperitoneal sarcoma received CIRT.
  • Histologic diagnoses were as follows: malignant fibrous histiocytoma in 6, liposarcoma in 3, malignant peripheral nerve sheath tumor in 3, Ewing/primitive neuroectodermal tumor (PNET) in 2, and miscellaneous in 10 patients.
  • [MeSH-major] Carbon Radioisotopes / therapeutic use. Neoplasm Recurrence, Local / radiotherapy. Retroperitoneal Neoplasms / radiotherapy. Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon. Female. Follow-Up Studies. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Radiodermatitis / pathology. Radiotherapy Dosage. Relative Biological Effectiveness. Survival Rate. Tomography, X-Ray Computed. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467578.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 7440-44-0 / Carbon
  •  go-up   go-down


98. Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, Burrell K, Croul S, Gutmann DH, Guha A: Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int J Cancer; 2010 Jan 15;126(2):563-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
  • Neurofibromatosis type 1 (NF1) patients are prone to the development of malignant tumors, the most common being Malignant Peripheral Nerve Sheath Tumor (MPNST).
  • NF1-MPNST patients have an overall poor survival due to systemic metastasis.
  • Recently, the NF1 gene product, neurofibromin, was shown to negatively regulate the phosphoinositide-3-kinase (PI3K)/Protein Kinase-B (Akt)/mammalian Target Of Rapamycin (mTOR) pathway, with loss of neurofibromin expression in established human MPNST cell lines associated with high levels of mTOR activity.
  • We developed and characterized a human NF1-MPNST explant grown subcutaneously in NOD-SCID mice, to evaluate the effect of the mTOR inhibitor rapamycin.
  • We demonstrate that rapamycin significantly inhibited human NF1-MPNST mTOR pathway activation and explant growth in vivo at doses as low as 1.0 mg/kg/day, without systemic toxicities.
  • While rapamycin was effective at reducing NF1-MPNST proliferation and angiogenesis, with decreased CyclinD1 and VEGF respectively, there was no increase in tumor apoptosis.
  • [MeSH-major] Neurofibromatosis 1 / drug therapy. Peripheral Nervous System Neoplasms / drug therapy. Sirolimus / pharmacology. Xenograft Model Antitumor Assays
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Blotting, Western. Cyclin D1 / metabolism. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Humans. Immunohistochemistry. Male. Mice. Mice, Inbred NOD. Mice, SCID. Protein Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Ribosomal Protein S6 Kinases / metabolism. Signal Transduction / drug effects. TOR Serine-Threonine Kinases. Tumor Burden / drug effects. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634141.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Vascular Endothelial Growth Factor A; 136601-57-5 / Cyclin D1; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


99. Demetriades AK, Saunders N, Rose P, Fisher C, Rowe J, Tranter R, Hardwidge C: Malignant transformation of acoustic neuroma/vestibular schwannoma 10 years after gamma knife stereotactic radiosurgery. Skull Base; 2010 Sep;20(5):381-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of acoustic neuroma/vestibular schwannoma 10 years after gamma knife stereotactic radiosurgery.
  • Only a handful of cases of de-novo malignancies of the vestibulocochlear nerve have been reported.
  • Even rarer is the malignant transformation of a previously histologically diagnosed benign vestibular schwannoma.
  • We present the case of a young adult who had combined operative/Gamma knife treatment for a benign vestibular schwannoma, followed by further surgery 2 years later.
  • He represented 10 years after original diagnosis with facial numbness and ataxia, MRI showing gross tumor recurrence.
  • After radical resection, histology showed malignant transformation to a malignant peripheral nerve sheath tumor.
  • Histology confirmed further de-differentiation to an anaplastic sarcoma.
  • While awaiting radiotherapy the tumor recurred again, the patient succumbing.
  • In the literature there are 13 other cases of malignant vestibular schwannomata.
  • The tumor biology of vestibular schwannomata as well as the radiobiology in the context of malignant transformation is discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1983 Oct 25;11(20):7191-203 [6634412.001]
  • (PMID = 21359005.001).
  • [ISSN] 1532-0065
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3023338
  • [Keywords] NOTNLM ; Gamma knife radiosurgery / Vestibular schwannoma / acoustic neuroma / anaplastic sarcoma / malignant peripheral nerve sheath tumor (MPNST) / malignant transformation / radiotherapy
  •  go-up   go-down


100. Gachiani J, Kim D, Nelson A, Kline D: Surgical management of malignant peripheral nerve sheath tumors. Neurosurg Focus; 2007;22(6):E13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of malignant peripheral nerve sheath tumors.
  • OBJECT: The aim of this study was to describe the presentation of patients harboring soft tissue sarcomas involving the nerves, most of which were malignant peripheral nerve sheath tumors (MPNSTs), and provide an algorithm for their treatment.
  • Tumor classifications are presented, together with patient numbers, locations of MPNSTs, surgical techniques, and adjunctive treatments.
  • CONCLUSIONS: Malignant peripheral nerve sheath tumors are rare.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Disease Management. Humans. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613204.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement